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Abstract 
              The emergence of bacterial strains with resistance to most known antibiotics has 
raised an urgent need for the development of new antimicrobial agents in order to avoid 
a serious threat to public health and return to the pre-antibiotic era. The ‘Trojan Horse’ 
strategy is one of the approaches that has been explored to evade membrane – based 
resistance mechanisms by smuggling the antibiotic in through the bacterial cell 
membrane(s).  
              The ‘Trojan Horse’ strategy involves conjugating a siderophore, sugar or an 
amino acid moiety to an antimicrobial agent to allow more effective antimicrobial 
transport. They can be conjugated through a non-biolabile or a biolabile linker; both 
types of the ‘Trojan Horse’ conjugates were prepared based on the antibiotic 
ciprofloxacin and alanine (Ala) and di-alanine (Ala-Ala). The conjugates were screened 
against wild type E. coli to compare the minimum inhibitory concentrations 
(MIC)/minimum bacterial concentrations with those of the free parent drug 
ciprofloxacin.  
               The conjugate coupled through a non-biolabile linker, Ala-Ala-ciprofloxacin, was 
found to have a very significant reduced antimicrobial activity compared to the parent 
drug with no evidence of active transport by peptide transporters. A DNA gyrase assay 
revealed that the conjugate was no longer an effective DNA gyrase-inhibitor.  
              The conjugates coupled through the biolabile disulfide linker, ciprofloxacin-
disulfide-Ala and ciprofloxacin-disulfide-Ala-Ala, were found to have retained some 
antimicrobial activity although lower than that of the parent drug. The conjugates 
reached a peak OD650 of 3.0 at 0.1 μM whereas ciprofloxacin reached a peak OD650 of 1.0 
at the same concentration. No evidence of transport by peptide transporters was 
observed. The retained antimicrobial activity suggested that intracellular cleavage of the 
disulfide linker occurred releasing free ciprofloxacin however the reduced antimicrobial 
activity could be due to inefficient cleavage of the disulfide bond or inefficient 
intracellular release of ciprofloxacin due to slow formation of the thiirane ring allowing 
re-formation of a disulfide bond.  
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Chapter 1. Introduction 
 
1.1. Antibiotics 
              The first antibiotics were discovered in the early 20th century and these included 
sulphonamides 1 (1930s), penicillin 2 (1940s), and towards the latter half of the 20th 
century quinolones 3 (1960s) were discovered.1 During the early period of antibiotic 
usage, antibiotics were being used to treat potentially lethal bacterial infections and as a 
result these infections were no-longer life-threating.2 
 
Figure 1: Members of classes of antibiotics; sulphonamides, penicillin and quinolones 
 
              Until the latter part of the 20th century, infections derived from most bacterial 
strains could be treated.1 However, the widespread use/misuse of antibiotics has 
promoted the emergence of more antibiotic-resistant organisms including multi-drug 
resistant (MDR) strains.2  
1.1.1. Antibacterial resistance 
              Bacterial organisms can share resistance genes if they come in close contact, 
resistance genes are either carried on the chromosomes of Wild-type (WT) bacteria or 
on elements of extrachromosomal DNA such as resistance (R) plasmids.2 
15 
 
There are various mechanisms through which antimicrobial resistant organisms express 
resistance; alteration/modification of the intracellular target site,  chemical/enzymatic 
degradation/inactivation of the antibiotic molecule, decreased permeability of the 
bacterial outer membrane and active antibiotic efflux2 (Figure 2).  
 
Figure 2: Schematic diagram of a plasmid containing antibacterial resistant genes 
illustrating the resistant mechanisms drawn based on Levy and Marshall3 
 
1.1.2. Alteration/modification of the intracellular target site  
               A variety of intracellular processes play an essential role in the growth and 
survival of bacterial organisms. Therefore, inhibition of these processes either leads to 
cell death or cell growth inhibition.4 In order to evade antimicrobial action, bacterial 
organisms develop mutational changes in the target site which reduces susceptibility 
whilst retaining cellular function.4 This type of mutation occurs, for example, in RNA 
polymerase resulting in resistance to rifamycins 4 and in DNA gyrase leading to 
resistance to quinolones 3 respectively.4  
              Mutations in RNA polymerase and DNA gyrase reduces antimicrobial action 
whilst retaining cellular function. However, mutations of Mec A in S. aureus, which 
imparts resistance to methicillin 2 and most β-lactam antibiotics, requires other changes 
in the cell to compensate for the mutations in order to retain cellular function.4 
16 
 
 
Figure 3: Structure of a rifamycin 
 
1.1.3. Antibiotic inactivation/degradation 
              The chemical modification of antibiotics catalysed by enzymes results in covalent 
modification of the antibiotic preventing strong interaction with the intracellular target.5 
An example of antibiotic chemical modification is the degradation of β-lactam 
antibiotics. The activity of β-lactam antibiotics is based on the strained electrophilic 
lactam ring which binds to penicillin binding proteins (PBPs) blocking the active site 
therefore impairing cell growth and division.5 β-lactam antibiotics are inactivated by the 
enzyme β-lactamase which hydrolyses the β-lactam ring to yield a ring opened structure5 
as shown in Figure 4.   
 
Figure 4: The hydrolysis of a β-lactam antibiotic (methicillin) by β-lactamase 
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1.1.4. Efflux pumps                      
              Both Gram-positive and Gram-negative bacteria have efflux pumps to remove 
toxic compounds from the cell. However Gram-negative bacteria have the more complex 
efflux system due to the two cell-envelope membrane and their most important efflux 
systems are the resistance, nodulation and division (RND) systems.6 According to studies 
carried out by Hancock et al. efflux systems are co-determinant resistance mechanisms, 
however, overexpression of certain pumps can result in resistance to a variety of 
antibiotics.6  
1.1.5. Reduced Permeability  
              The outer membrane of Gram-negative bacteria consists of porin proteins, a 
transport channel through which hydrophilic compounds such as fluoroquinolones and 
β-lactams enter the periplasm.6 Bacteria exhibit resistance to these compounds by down 
regulation of porins and/or mutation of a porin gene.6 Mutations of the porin gene could 
lead to the porin’s single-channel conductance being lowered and lack of voltage 
sensitivity as observed for the porin from the resistant strain of Enterobacter 
aerogenes.7  
              The outer membrane of Gram-negative bacteria also consists of a bilayer which 
has lipopolysaccharides (LPS) on the outer leaflet of the membrane.6 LPS are highly 
anionic due to the phosphate groups within their structure. This anionic nature 
promotes the cross-bridging of the core region of the LPS with divalent cations such as 
Mg2+ and Ca2+ cations.6 The cross-bridging stabilises the polyanionic external surface of 
the outer membrane and according to Hancock et al. this surface stabilisation is thought 
to inhibit the partitioning of hydrophobic antibiotics into the hydrophobic bilayer leading 
to the slow uptake of hydrophobic antibiotics.6 
1.1.6. Overcoming bacterial resistance  
              In order to overcome bacterial resistance, new antibiotics need to be developed; 
antibiotics that either block or circumvent resistance mechanisms or that attack new 
targets.3 Currently there has been a lack of development of new antibiotics as genomics 
has not delivered the anticipated novel therapeutics and also pharmaceutical industry 
has reduced its research efforts in infections.1 The pharmaceutical industry has reduced 
antibiotic research and development due to a number of reasons including poor return 
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on investment, increasing cost of drug development and the increasing demand for 
more safety data.1  
1.1.6.1 Combination therapy 
              Various strategies have been developed to overcome bacterial resistance 
including combination therapy and the chemical modification of antibiotics to target 
resistance mechanisms. Oxazolidinone-quinolone hybrids 5 are an example of 
combination therapy with potent antibacterial activity higher than that of the free 
parent drugs, the hybrids simultaneously act on two different cellular functions; with the 
oxazolidinone acting on protein synthesis and the quinolone on DNA replication.8   
 
Figure 5: Structure of an oxazolidinone-quinolone hybrid 
 
1.1.6.2 Overcoming membrane-based resistance 
              Chemical modification of existing antibiotics by conjugating the antibiotic to a 
biologically essential nutrient such as iron has been observed to bypass membrane-
based resistance mechanisms, this is known as the ‘Trojan Horse’ strategy.9 
Permeabilizing agents like antimicrobial polycationic compounds have been 
investigated, polycationic antimicrobials interact with LPS on the surface of the outer 
membrane through electrostatic bonding as the LPS are highly anionic.6 
               Hancock et al. states that polycationic antimicrobials have higher affinity for the 
LPS than divalent cations, therefore the polycationic antimicrobials competitively 
displace divalent cations on the surface of LPS leading to distortion of the outer 
membrane structure and the membrane becomes permeable to various antibiotics as 
well as the polycationic antimicrobials.6 
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1.2. Introduction to fluoroquinolones 
              The first quinolone antibiotics were discovered in 1962 by George Lesher and co-
workers as by-products in chloroquine synthesis.10 Chloroquine 6 is a drug used in the 
treatment or prevention of malaria. The by-product 7 showed anti Gram-negative 
activity but its potency and antimicrobial spectrum was not significant enough to be 
used as a therapy.11 Nalidixic acid 3 was found to have excellent activity against Gram-
negative bacteria such as E. coli and A. aerobacter and it was used for the treatment of 
urinary tract infections, however it was generally inactive against Gram-positive bacteria 
such as S. aureus.10  
Figure 6: Structures of nalidixic acid 3, chloroquine 6 and chloroquine by-product 7  
              Other first generation quinolones such as oxolinic acid and cinoxacin (Figure 7) 
were introduced but their limited activity against Gram-negative bacteria and poor 
systemic distribution led to the introduction of fluoroquinolones.12 The 
fluoroquinolones, ciprofloxacin and norfloxacin (Figure 7), were developed in the 1980s 
and they have an extended spectrum of activity and improved pharmacokinetics with 
increased activity against Enterobacteriaceae and many Gram-positive organisms.13 
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Figure 7: First and second generation quinolone antibiotics 
              This significant improvement was due to critical changes of the quinolone 
skeleton with the introduction of a fluorine at position C6 and a piperazine at position C7 
13 hence the name “fluoroquinolones”. The piperazine is believed to enhance potency 
and favourable pharmacokinetics whilst the fluorine at C6 broadens the spectrum of 
activity.11 
              Ciprofloxacin was the first fluoroquinolone to show significant activity outside of 
the urinary tract and it is the most widely used antibacterial drug against Gram-negative 
bacteria strains.14 Ciprofloxacin is chemically related to norfloxacin, – with modification 
of the ethyl group on N1 position to a cyclopropane. This modification improved both 
oral absorption and systemic distribution of the fluoroquinolone, therefore, allowing the 
use of ciprofloxacin for a variety of tissue infections including the lower respiratory tract 
in addition to urinary tract infections.15 
              Although the second generation fluoroquinolones have a broad spectrum of 
activity they have moderate activity against many but not all Gram-positive strains. 
Therefore, fluoroquinolone research has been aimed at developing fluoroquinolones 
with improved activity against Gram-positive strains whilst maintaining the activity 
against Gram-negative organisms. 
 
 
1.2.1. Development of fluoroquinolones  
              A third generation fluoroquinolones was developed (Figure 8). These 
fluoroquinolones; moxifloxacin, levofloxacin and trovafloxacin have enhanced activity 
against Gram-positive organisms whilst retaining excellent activity against Gram-
negative organism.13  Trovafloxacin was found to be more active than ciprofloxacin, 
showing activity against the Gram-positive penicillin-resistant S. pneumoniae and 
anaerobe infections whilst retaining activity against Gram-negative strains.15 However 
trovafloxacin has been withdrawn due to serious hepatotoxicity.16 
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Figure 8: Structures of the third generation of fluoroquinolones 
              Modifications to the basic chemical structure of the quinolone has produced 
compounds with an extended spectrum of activity and improved pharmacokinetics 
therefore there is hope for ‘newer’ generations of fluoroquinolones. It is important to 
retain certain groups in the fluoroquinolone core structure when designing new 
compounds as some of the functional groups are essential for antimicrobial activity.  
 
Figure 9: Fluoroquinolone pharmacophore showing sites that can be modified (R, R1 and 
R2) 
             Positions N1, C2, C3, C4 and C6 (Figure 9) are indispensable for activity of the 
fluoroquinolone therefore modifications at these sites are not favourable.11 
Substitutions at C5 are tolerated if the substituents are small (methyl) and preferably 
polar (amine) groups.11 C7 is the most adaptable position, usually cyclic systems 
containing a secondary or tertiary amino moiety are introduced.11 Successful C8 
substituents have been found to be nitrogen. C8 halogens have been found to enhance 
the likelihood of phototoxicity.11 Substituents on the N1 nitrogen have been mainly 
cyclopropyl and aryl groups. 
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              Recently a new fluoroquinolone, ABT-492, (Delafloxacin) was synthesised.17The 
drug is still under investigation and has been designated as a Qualified Infectious Disease 
Product (QIDP) by the U.S Food and Administration (FDA). 
 
Figure 10: Structure of delafloxacin 
              The intracellular target for all quinolone antibiotics is DNA gyrase or 
topoisomerase IV; DNA gyrase is the primary target of quinolones in Gram-negative 
bacteria whereas topoisomerase IV is mainly targeted in Gram-positive bacteria.  
 
1.2.2. Mode of action of DNA gyrase 
              Bacteria express two related type II topoisomerases which are essential for 
bacterial growth; DNA gyrase and topoisomerase IV. DNA gyrase is an A2B2 tetrameric 
complex that catalyses the negative supercoiling of circular chromosomal DNA using free 
energy derived from ATP hydrolysis18,19 (Figure 11) and topoisomerase IV which 
mediates topological unlinking of catenated daughter chromosomes.19 
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Figure 11: Schematic diagram of DNA gyrase mechanism of action, drawn using 
information obtained from Gmunder et al   
1.2.3. Mode of action of quinolones 
              Quinolones have been found to bind poorly to relaxed double-stranded DNA, 
they preferentially bind to single-stranded DNA by forming hydrogen bonds with the 
unpaired bases.20 However, they were found to have enhanced drug binding to relaxed 
DNA in the presence of the enzyme DNA gyrase and ATP, therefore, it was suggested 
that bound DNA gyrase induces a binding site for quinolones in the relaxed DNA which in 
turn inhibits the enzyme.20 
              DNA gyrase induces this binding site by forming a single-stranded DNA pocket 
where the drug binds and locks DNA and enzyme in place20 (Figure 12).The drug-
stabilized gyrase complex then acts as a physical block to ligation of the break leading to 
cell apoptosis.14 
 
Figure 12: Diagram drawn from an adaptation of Shen et al. Quinolone-DNA stabilised 
complex inhibiting DNA gyrase (an A2B2 complex) with the dotted lines representing 
hydrogen bonding between the DNA strands and the quinolone molecules20 
              Shen et al. hypothesised that the drug self-associates within the pocket through 
hydrogen bonds between the DNA bases (N-H groups) and the hydrogen bond acceptors 
on the quinolone rings (C=O groups).20 The drugs also interact through (i) ∏-∏ ring 
stacking of adjacent quinolone rings (ii) tail-to-tail hydrophobic interactions between N1 
hydrophobic groups of drug molecules bonded to two opposite DNA strands.20 
              Shen et al. suggested that the number of drug molecules that can bind depends 
on the size and the configuration of the binding site with the proposed model having 
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four quinolone molecules bound per complex.20 However Laponogov et al. established 
that only two quinolone molecules are present in the drug-stabilised complex19(Figure 
13).  
 
Figure 13: Diagram showing self-association of fluoroquinolones (ciprofloxacin) in the 
DNA binding pocket showing hydrogen bonding between the DNA bases and 
ciprofloxacin (represented by dashed lines) and tail-to-tail hydrophobic Interactions 
between the cyclopropane rings of ciprofloxacin. Interaction of DNA gyrase is not shown 
for clarity20 
 
1.2.4. Plasmid-mediated resistance 
              There are three families of genes that cause plasmid-mediated quinolone 
resistance; Qnr genes, aac(6’)-Ib-cr proteins and efflux pumps.  
              Qnr genes protect DNA gyrase and topoisomerase IV from quinolone inhibition 
by two mechanisms: (i) Qnr proteins act as DNA mimics and compete with DNA for 
binding to the enzyme therefore lowering the number of enzyme-DNA complexes 
available for quinolone binding, (ii) they inhibit quinolones from entering the binding 
pocket on enzyme-DNA complex.21  
              Aac(6’)-Ib-cr enzyme is a variant of an aminoglycoside acetyltransferase that 
includes two mutations which reduce aminoglycoside resistance but confer resistance to 
ciprofloxacin and norfloxacin.22 This enzyme acetylates the unsubstituted nitrogen of the 
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C7 piperazine ring reducing drug activity. Acquisition of aa(6’)-Ib-cr was found to 
increase ciprofloxacin MICs 2- to 4-fold.22   
              Only three plasmid-encoded efflux pumps have been identified so far; QepA1 
and QepA2 found in human bacterial infections and OqxAB found in animal infections.14 
1.2.5. Chromosome-mediated resistance 
              Quinolone intracellular concentration is controlled by the opposing actions of 
diffusion-mediated drug uptake and pump-mediated efflux. Therefore, overexpression 
of chromosome-encoded efflux pumps reduces the intracellular concentration of 
quinolone in bacterial cell.14 In Gram-negative bacteria quinolone resistance can also be 
regulated by altering expression of outer membrane porin proteins (OmpF and OmpC in 
E. coli) that form channels for passive diffusion.23 Both Gram-positive and Gram-negative 
bacteria have non-specific, energy-dependent efflux systems.23 
1.2.6. Overcoming quinolone resistance  
              Most common cause of high-level quinolone resistance is mutations in DNA 
gyrase and/or topoisomerase IV therefore an ideal fluoroquinolone would be one that 
retains activity against these mutated enzymes, however no such drug has been 
reported.14 In theory, designing a fluoroquinolone-like drug that does not depend on the 
water-metal ion bridge for primary interaction with gyrase or topoisomerase IV would 
overcome target-mediated resistance.14  
              Membrane-based resistance such as permeability resistance can be overcome by 
conjugation of the antibiotic to an actively transported bacterial nutrient as this will 
allow the exploitation of bacterial cell nutrient transport mechanisms.9 
1.3. Overview of ‘Trojan Horse’ strategy 
              The main concept of the ‘Trojan Horse’ strategy involves conjugation of an 
antibacterial moiety to a nutrient molecule (or nutrient-binding molecule) that is 
required for bacterial growth. This is done in order to bypass membrane-based 
resistance mechanisms. Nutrients that can be used include iron-(III), carbohydrates or 
peptides with bacterial iron transport being the ideal target due to the delicate balance 
of iron homeostasis in all organisms.9 
26 
 
              A general nutrient (or nutrient-binding molecule)-drug conjugate system (Figure 
14) consist of three components, (i) Nutrient- to increase uptake of the drug (ii) linker 
which connects the drug moiety to the nutrient (iii) the drug. 
 
 
Figure 14:  An illustration of a general nutrient-drug conjugate system 
              Naturally occurring ‘Trojan Horse’ conjugates have been isolated from various 
microorganisms, some of the conjugates are albomycins24 and salmycin25 (Figure 15) 
which both contain a siderophore (iron binder) component that chelates the iron 
nutrient and an antimicrobial component. 
 Figure 15: Structures of the natural ‘Trojan Horse’ conjugates; albomycins and salmycin 
              The natural design of ‘Trojan Horse’ conjugates was applied to synthesise 
artificial siderophore conjugates. The first synthetic ‘Trojan Horse’ conjugate 8 was 
synthesised in 1977 by Zähner et al. using hydroxamate siderophores.26 
Nutrient Linker Drug 
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Figure 16: Structure of one of the first synthetic siderophore conjugate with a 
sulphonamide as the antibiotic moiety 
              The concept of using synthetic siderophores has developed and a clear benefit of 
using β-lactam antibiotics as a drug moiety, many examples have been reported of 
potent antimicrobial activity including siderophore aminopenicillin 9 conjugates,9 
ampicillin and amoxicillin 10 conjugates27 (Figure 17) . β-lactam antibiotics target 
penicillin binding proteins (PBPs) which are located in the periplasm therefore only need 
to cross the bacterial outer membrane to gain access.9 Also compared to most other 
antibiotics, β-lactam drugs have two separate sites for target attachment therefore the 
entire conjugate is capable of binding to the target without releasing the siderophore 
moiety.9 
28 
 
 
Figure 17: Synthetic siderophores using β-lactam antibiotic as the drug moiety 
              Although the β-lactam siderophore conjugates proved to be successful, nearly all 
other siderophore-drug conjugates with an antibiotic component that have a 
cytoplasmic target have shown decreased activity compared to the free drug alone.28 
This posed a question of whether drug release is essential for antimicrobial activity of 
siderophore-drug conjugates. 
              Wencewicz et al. and colleagues conducted a study of desferridanoxamine-
antibiotic conjugates (Figure 18) to understand the role of drug release in siderophore-
mediated drug delivery.28 Desferridanoxamine (Dan) is an effective growth promoter for 
Gram-negative and Gram-positive bacteria; the antibiotics used for the study included 
Lorabid® (Lor), ciprofloxacin (Cip) and trisclosan (Tri). Wencewicz et al. concluded that 
for siderophore-drug conjugates with intracellular targets, an active drug release process 
is needed for antimicrobial activity as all conjugates linked with a non-labile amide linker 
(Dan-Lor 11 and Dan-Cip 12 conjugates) were less active than the free drug while Dan-Tri 
13 conjugate which was linked through a bio-labile ester linker had equal or greater 
activity compared to the free drug alone.28 
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 Figure 18: Desferridanoxamine-antibiotic conjugates; Dan-Lorabid (Dan-Lor), Dan-
ciprofloxacin (Dan-cip) and Dan-Trisclosan (Dan-Tri) 
              The ‘Trojan Horse’ strategy has also been applied to other fluoroquinolone 
antibiotics using different nutrients to synthesise alternative ‘Trojan Horse’ conjugates; 
siderophore-fluoroquinolone conjugates9 and glycosylated-fluoroquinolone 
conjugates.29 
 
1.3.1. Siderophore-fluoroquinolone conjugates 
              Mislin et al. carried out a study of pyochelin-norfloxacin conjugates (Figure 19) 
to test the conjugates and the effect of the linker on antimicrobial activity of the 
antibiotic.30 Pyochelin is a siderophore of Pseudomonas aeruginosa pathogen and the 
researchers observed that only conjugates with a labile linker 14 showed antibacterial 
activity whereas conjugate 15, with non-labile linker, had no activity. Therefore it was 
suggested that the presence of the siderophore may prevent the antibiotic from 
interacting with its target (DNA gyrase) due to steric hindrance.30  
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Figure 19: Structures of pyochelin-norfloxacin conjugates with a labile linker 14 and with 
a non-labile linker 15 
              Citrate-ciprofloxacin conjugates 16 and 17 (Figure 20)31 were reported by 
Duhme-Klair/Routledge research groups, they observed that the conjugates retained 
some antimicrobial activity, however activity was significantly reduced compared to that 
of free ciprofloxacin. The effect of the length of the linker on antimicrobial activity was 
also investigated by introducing a glycine 18 and aminovaleric acid spacer 19.31 The 
insertion of a spacer was found to cause a significant reduction in activity especially with 
conjugate 19 therefore it was suggested that a non-biolabile spacer should not contain 
more than 1-2 atoms.31 The reduction in activity was proposed to be due to less stable 
binding to DNA gyrase. 
              A study of staphyloferrin-ciprofloxacin conjugates (Figure 21) was also carried 
out to assess whether the modification of ciprofloxacin with racemic staphyloferrin 
altered the antimicrobial activity of ciprofloxacin.32 Both conjugates displayed a 
significant reduction in activity against strains that were susceptible to ciprofloxacin, this 
reduction in activity was thought to be due to incomplete inhibition of the DNA gyrase 
potentially due to steric clashes of the modified drug and/or electrostatic repulsions.32 
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Figure 20: Structures of citrate-ciprofloxacin conjugates 
 
Figure 21: Structure of ornithine-based staphyloferrin ciprofloxacin conjugates 
 
1.3.2. Glycosylated-fluoroquinolone conjugates  
               Although detailed investigations in the use of iron bacterial transport systems in 
‘Trojan Horse’ antibiotics have been conducted, bacterial carbohydrate transporters 
have been studied to a much lesser extent with the first carbohydrate based ‘Trojan 
Horse’ conjugates reported in 1999 by Jung et al.33 
              Monosaccharides glucose and galactose were conjugated to ciprofloxacin33 and 
norfloxacin.34 In bacteria, glucose and galactose monosaccharides can be transported 
through proton symport35 and the phosphoenolpyruvate-dependent sugar: 
phosphotransferase system (PEP-PTS).36 The monosaccharide-ciprofloxacin conjugates 
were tested for their antimicrobial activity as well as the effect of adding a linker to the 
conjugate.  
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              The monosaccharide-ciprofloxacin conjugates with no linker, 20 and 21 were 
found to retain antimicrobial activity comparable to free ciprofloxacin however 
conjugates with a linker, 22 and 23 had significantly reduced activity compared to the 
free ciprofloxacin but the glucose conjugate 22 displayed higher activity than the 
galactose conjugate 23.33 It was suggested that the conjugates were being actively 
transported but no definite evidence was provided. 
 
Figure 22: Glucose and galactose-ciprofloxacin conjugates with no linker, 20 and 21, and 
with linker, 22 and 23 
              A further investigation of the monosaccharide-ciprofloxacin conjugates was 
carried out by Routledge/ Duhme-Klair research groups to determine if these conjugates 
were being actively transported or being transported through fluoroquinolone uptake 
mechanisms and/or passive diffusion.29 Glucose-ciprofloxacin conjugate 22, galactose-
ciprofloxacin conjugate 23 and lactose-ciprofloxacin conjugate 24 were synthesised with 
propyl linkers. Conjugates 22 and 23 retained antimicrobial activity but lower than that 
of free ciprofloxacin and 24 showed no activity. It was suggested that adding lactose to 
ciprofloxacin has a significant effect on the ability of ciprofloxacin to inhibit DNA gyrase 
compared the effect observed following addition of galactose and glucose. 
 
Figure 23: Structure of lactose-ciprofloxacin conjugate with a biostable linker 
              No evidence was found to support the active transport of the monosaccharide-
ciprofloxacin conjugates across the cytoplasmic membrane but there was evidence 
which suggested that the conjugates were diffusing through porins to penetrate the 
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outer membrane then probably diffusing at a lower rate through the inner membrane to 
reach their target.29 Therefore, it was concluded that the use of carbohydrate based 
‘Trojan Horse’ conjugates to exploit the carbohydrate transport system could essentially 
be flawed. 
 
1.3.3. Peptide-drug conjugates 
              In order to improve the absorption of drugs with low oral bioavailability, 
peptide-‘Trojan Horse’ conjugates have been synthesised to target specific carrier 
proteins. Mitra et al. conducted a study on lopinavir; a protease inhibitor used for the 
treatment of HIV infection.37 Lopinavir has low bioavailability which is thought to be due 
to extensive metabolism by CYP3A438 and lopinavir is also a substrate for the efflux 
transporters P-glycoprotein (P-gp) and Multidrug Resistance Protein (MRP2).39 
              Lopinavir-valine-valine 25 and Lopinavir-glycine-valine 26 conjugates were 
synthesised to study their uptake and transport across the MDCKII-MDR1 and MDCKII-
MRP2 cell membrane. Both conjugates were found to be substrates of peptide 
transporters expressed on the intestinal barrier as they displayed better solubility, 
metabolism and internal permeability profiles compared to the parent drug lopinavir.37 
This indicates that the conjugates were able to circumvent P-gp and MRP2 mediated 
efflux. 
 Figure 24: Structures of Lopinavir-valine-valine 25 and Lopinavir-glycine-valine 26 
 
              Peptide based conjugates were also applied to target other peptide transporters, 
Foley et al. synthesised two peptide based conjugates using nabumetone linked through 
a hydrolysable linker to a thiodipeptide.40 The conjugates were designed to target 
transport via PepT1, an intestinal peptide transporter. 
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1.3.4. Peptide Trojan Horse conjugates 
               Routledge/Duhme-Klair research groups synthesised peptide based conjugates; 
ciprofloxacin-Gly-Gly 27 (a control that should not be actively transported) and 
ciprofloxacin-L-Ala 28 to investigate their transport in bacteria. These conjugates were 
designed to target the ABC transporters and proton symporters (PTRs) in E. coli, which is 
explained in detail in section (1.4). Tests were conducted using mutated E. coli species 
with ABC transporters knocked out or PTR knocked out and wild type E. coli as a control 
organism. 
 
Figure 25: Structures of glycine-glycine-ciprofloxacin 27 and L-alanine-ciprofloxacin 28 
              Although both conjugates retained antimicrobial activity, the activity was 
significantly lower than that of free ciprofloxacin and no growth advantage was 
observed for the ABC or PTR knock outs. This suggests that 28 was not being transported 
via peptide transporters (unpublished results). However this conclusion was not 
conclusive and further investigations are described in this thesis.  
1.4. Peptide Transporters 
1.4.1. ABC transporters  
              ABC transporters are associated with many important biological processes in 
both prokaryotes and eukaryotes and they are characterised by their highly conserved 
ATP-binding cassette.41 ABC transporters utilize the energy of ATP hydrolysis to pump 
substrates across the membrane against a concentration gradient.41 Typical ABC 
transporters consists of four membrane-associated domains (i) two highly hydrophobic 
transmembrane domains which form the pathway for substrates to cross through the 
membrane and these domains are thought to be the substrate specificity domains (ii) 
two ATP binding domains which are highly hydrophilic, these are located at the 
35 
 
cytoplasmic face of the membrane, they bind ATP and couple ATP hydrolysis to the 
transport process.41 
 
Figure 26: A diagram drawn based on Higgins et al showing the domains of a typical 
bacterial ABC transporter and where the domains are located within a bacterial cell41 
              In addition to the four core domains, all bacterial ABC transporters require a 
substrate-binding protein in the periplasmic space.41 These periplasmic proteins (also 
known as oligopeptide-binding proteins) are essential for the function of the transport 
system; they are made up of two globular domains and a cleft that forms the substrate-
binding site. They serve as the initial receptor for transport therefore play a role in 
determining substrate specificity.41 Although periplasmic-binding proteins are involved 
in determining substrate specificity, transmembrane domains are the primary 
determinants.41 
 
1.4.1.2. Substrate specificity  
              Study of the oligopeptide-binding protein OppA from E. coli was carried out to 
investigate the peptide substrates.42 The binding protein was found to have little or no 
affinity for free amino acids and dipeptides but high affinity for tripeptides, it also 
demonstrated preference for peptides with unmodified amino termini, although it was 
still able to transport peptides with modified C-termini the binding protein requires 
peptide substrates to possess free amino termini.42 Tripeptides with hydrophobic or 
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polar side chains such as alanine and serine had higher affinity for the binding site 
compared to peptides with ionic side chains like glutamic acid.42 
1.4.2. Overview of POT family transporters   
              Proton-dependent oligopeptide (POT/PTR) transporters, PepT1 and PepT2, 
belong to the major facilitator superfamily (MFS) of secondary active transporters; they 
actively transport di-and tri-peptides across membranes.43 PepT1 and PepT2 also 
transport a number of drugs and amino acid-conjugates prodrugs across the cell 
membrane. Therefore, a detailed understanding of substrate recognition could allow the 
modification of pharmacologically active compounds into substrates for PepT1 and 
PepT2 transport therefore improving bioavailability and distribution.44 
              PepT1 and PepT2 are proton (H+)-driven symporters that use the inwardly 
directed proton electrochemical gradient to drive uptake of peptides across membranes 
through a transport mechanism known as the rocking bundle mechanism.43 The rocking 
bundle mechanism is a transport mechanism which MFS use; MFS transporters consist 
of two 6 trans-membranes bundles that assemble together in the membrane to form a 
‘V’-shaped transporter with a central binding site formed between the two bundles.43 
PepTso (Shewanella oneidensis) crystal structure was the first crystal structure of a POT 
transporter to be determined which revealed a novel asymmetrical occluded 
conformation and a conserved intracellular gate.45  
1.4.2.2. Mode of action 
              Structural and conformational studies of a POT family transporter from the 
bacterium S. thermophiles, PepTst, was carried out.
43 It was concluded that the N-
terminal domain of the binding site dictates peptide binding and affinity characteristics 
while the C-terminal domain is more dynamic and facilitates the opening and closing of 
the peptide-binding site; alternating salt bridge interactions that form and break during 
transportation at both the extracellular and intracellular ends of the peptide-binding site 
were also proposed.43 The proposed salt bridge networks have been suggested to have 
an important role in many secondary active transporters; they are suggested to be 
important for orchestrating structural re-arrangements during transport.46 
              The mechanism of transport of PepTst was proposed to be through three 
conformations; outward-facing, occluded and inward-facing.43 In the outward-facing 
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state, the central binding site is accessible to the extracellular side of the membrane to 
allow peptides to enter the binding site but closed to the intracellular end by a salt 
bridge formed between Lys126 of helix 4 (H4) and Glu400 of (H10).43 The PepTst then 
transitions to the occluded state after proton and peptide binding.  
 
Figure 27: Schematic diagram drawn based on Solcan et al showing the mode of action 
of PepTst transporter through three states; outward-facing, occluded and inward-facing 
states43  
              The occluded state is closed to both the exterior and the interior of the cell with 
the peptide occluded within the binding site. Transition of extracellular state to occluded 
state is facilitated by the substantial inter-helical movement within the C-terminal half of 
the transporter. This allows salt bridge interactions at two sites, Arg53 (H1)-Glu312 (H7) 
and Arg33 (H1)-Glu300 (H7), therefore allowing the closure of the extracellular gate.43   
              The PepTst then transforms from the occluded state to the inward-facing state 
which weakens one of the salt bridges, Lys126-Glu400.43 This transition occurs as a result 
of localised hinge-like bending in H10 helix which is in parallel to the movement of H7 
helix. Within the intracellular state the central cavity is accessible to the interior of the 
cell to enable the release of the bound peptide and proton.43 Once the peptide and the 
proton have been released the transport cycle then recycles back through an empty 
occluded state in-order to complete the cycle.43 
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1.4.2.3. Selectivity mechanism  
              The structure of a PepT transporter from S. oneidensis (PepTso2) crystallised with 
three different peptides was studied so as to gain an understanding of the structural 
information on peptide binding to PepT transporters.44 This study demonstrated that the 
PepT binding site prefers di-and tripeptides over single amino acids and also that the 
binding-site pockets (Pocket 1, 2 and 3) are tolerant of small-and medium-sized 
hydrophobic and aromatic side chains.44 It was also suggested that the PepT binding site 
has a highly conserved peptide backbone within the PepT family and this peptide 
backbone plays a large part in the recognition and affinity of substrates.44 
              L-valyl prodrug of zanamivir 29 (a treatment for influenza A and B infections) is 
an example of a successful prodrug that has been generated by linking the 
pharmaceutically active drug to the carboxylate group of a small amino acid.47 
 
Figure 28: Structure of L-valyl prodrug of zanamivir 
              The use of peptides as a nutrient of the ‘Trojan Horse’ strategy was adapted 
within this thesis (Figure 29) to exploit these peptide transport mechanism to actively 
transport the drug moiety across the bacterial inner membrane. 
   
 
Figure 29: An illustration of a peptide conjugated to a drug moiety through a linker 
              In the ‘Trojan Horse’ strategy studies have shown that the use of stable, non-
labile linkers compromises the activity of the pharmaceutically active drug, the nutrient 
or nutrient binding molecule may be sterically hindering therefore inhibiting the drug 
from interacting with its target. This was observed in a study carried out by Mislin et al. 
Peptide  Linker Drug 
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of pyochelin-norfloxacin conjugates (Figure 19) which showed that only conjugates with 
a labile linker had antibacterial activity comparable to that of the parent drug, 
norfloxacin.30 
1.5. Biolabile linkers  
             An ester linkage is an example of commonly used labile linker, Godtfredsen et al. 
synthesised linked esters of ampicillin (β-lactam antibiotic) and penicillanic acid sulfone 
(β-lactamase inhibitor) 30 so as to increase the oral absorption of β-lactam antibiotics as 
well protecting the lactam antibiotic from inactivation by β-lactamase.48 
 
Figure 30: Structure of a linked ester of ampicillin and penicillanic acid sulfone 
 
1.5.1. Disulfide linkers 
              The disulfide moiety has been applied in the development of many compounds 
including prodrugs.49 Glutathione disulfide (GSSG) 32 is one of the major biological 
disulfide compounds and is produced on oxidation of free glutathione (GSH) 31. A 
disulfide bond is relatively stable in mildly oxidising and physiological pH conditions but 
readily susceptible to the reductive disulfide cleavage reaction to generate two thiols, 
GSSG can be reduced back to GSH in the presence of the NADPH-dependent enzyme 
(Figure 31).49 
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Figure 31: Reversible changes between glutathione and glutathione disulfide 
              Disulfides have been incorporated in drug delivery strategies as they have 
demonstrated high biocompatibility, stability in the bloodstream and cleavage by 
disulfide reductase or metabolic thiols allowing the drug molecule to be released at the 
target site with high efficiency.49 All these properties makes a disulfide bond a suitable 
bio-labile linker as it can also accommodate various types of chemicals such as cytotoxic 
agents (Nitric oxide-Diclofenac prodrug 33) 50 and tumour-targeting molecules (RGD 
peptide-appended naphthalimide camptothecin 34).51 
 
Figure 32: Structures of Nitric Oxide-Diclofenac prodrug 33 and RGD peptide-appended 
naphthalimide camptothecin 34 
              Disulfide bonds have been utilized as linkers between constituent drugs in a 
mutual prodrug. A mutual prodrug is a form of prodrug which consists of two 
pharmacologically active agents attached to each other in a synergistic or additional way 
with one drug acting as a promoiety/carrier for the other drug.52 Synergistic association 
is when the carrier shows the same biological action as the parent drug and additional 
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association is when the carrier shows new pharmacological action which the parent does 
not have.52 
1.5.1.2. Release of disulfide-based prodrugs 
              Jain and co-workers designed and synthesised several novel mutual prodrugs 
containing drug-releasable disulfide linkers and proposed a plausible mechanism of drug 
release from the mutual prodrugs.53 It is proposed that in vivo Intracellular attack of the 
disulfide bond by sulfhydryl-containing species such as glutathione, at biological pH will 
lead to the release of the drug conjugates, ethylene monothiolcarbonate 35, ethylene 
sulfide 36, and the RS-S containing conjugate 37 which can be excreted.53 The active-
drug is released in the cytoplasm because the cytoplasm is maintained under reducing 
conditions by free thiols such as glutathione whereas the periplasm is maintained in an 
oxidative state, the free thiols cleave the disulfide bond allowing the release of the 
active drug.54  
Scheme 1: Mechanism of in vivo mutual prodrug release via ester hydrolysis and /or 
sulfhydryl-assisted cleavage. Where X =O, N and RSH and RSSR = reduced cellular 
Cysteine or Glutathione. Scheme adapted from Jain et al.53 
              The proposed drug release mechanism was supported by the mechanistic study 
which was carried out on the reported prodrugs. This study confirmed the formation of 
some important metabolites, ethylene monothiolcarbonate 35 and ethylene sulfide 36, 
therefore proving the mechanism to be plausible.53 A disulfide linker was proposed in 
the synthesis of conjugates described in this thesis to link the peptide nutrient to the 
drug; ciprofloxacin.  
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Figure 33: An illustration of a peptide conjugated to ciprofloxacin through a disulfide 
linker 
              The hypothesis of the thesis being that the conjugate diffuses across the 
bacterial outer membrane into the periplasm where it will be actively transported by the 
peptide transporters across the inner membrane into the reducing environment of the 
cytoplasm where the disulfide bond is cleaved by free thiols to release free ciprofloxacin 
(Scheme 2). 
 
 
 
Peptide Disulfide Ciprofloxacin 
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 Scheme 2: The proposed intracellular cleavage of ciprofloxacin-Ala conjugate 
 
 
 
 
 
  
 
 
 
1.6. Project Overview  
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              The synthetic aim of the project is to synthesise a ‘Trojan Horse’ conjugate with 
ciprofloxacin as the drug moiety (Figure 7) and an amino acid (Ala) and dipeptide (Ala-
Ala) as the nutrient conjugated to the carboxylic acid group of ciprofloxacin via an 
intracellular, reductively activated disulfide bond. Ala-Ala-ciprofloxacin conjugate 38 
with a non biolabile linker will also be synthesised to allow comparison with a previously 
synthesised Ala-ciprofloxacin conjugate 28 which was found to retain antimicrobial 
activity but lower than that of free ciprofloxacin (unpublished results). Ciprofloxacin acts 
as an amino acid mimic as it is zwitterionic with a nitrogen and carbonyl end which can 
be considered analogous to the N and C termini of amino acids. Therefore the 
conjugation of Ala-Ala through the peptide’s C termini to the nitrogen of the piperazine 
ring of ciprofloxacin will generate a pseudo tripeptide 38 which could potentially be 
recognised by bacterial peptide transporters.   
              Once ciprofloxacin-disulfide-Ala 39 and ciprofloxacin-disulfide-Ala-Ala 40 are 
synthesised, they will be used to investigate bacterial homologs of peptide transporters 
PepT1, PepT2 and ABC to actively transport the conjugate in E. coli. Once delivered in 
the cytoplasm the conjugate can be reduced by intracellular sulfhydryl-containing 
species releasing free ciprofloxacin. All synthesised conjugates (Figure 34) will be 
screened against wild type E. coli to compare the minimum inhibitory concentrations 
(MIC)/minimum bacterial concentrations with those of the free parent drug 
ciprofloxacin.  
The key objectives of the project are; 
 To synthesis ciprofloxacin ‘Trojan Horse’ conjugates with amino acids Ala and 
Ala-Ala conjugated via a biolabile disulfide bond or a non biolabile amide bond 
  Synthesised conjugates will be screened against wild type E. coli to compare the 
MIC/minimum bacterial concentrations with that of ciprofloxacin 
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Figure 34: Structures of peptide-ciprofloxacin conjugates conjugated via a non-biolabile 
linker 38 and a bio-labile disulfide linker 39 and 40 
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Chapter 2. Results and Discussions  
2.1. Synthesis of Ala-Ala-ciprofloxacin conjugate 38 via a non-biolabile amide  
              L-alanine is a hydrophobic amino acid and ABC transporters have higher affinity 
for peptides with hydrophobic side chains,41 however, they have little affinity for 
dipeptides compared to tripeptides.42 PTR secondary active transporters (PepT1 and 
PepT2) are known to transport a number of amino acid prodrugs across the cell 
membrane43 with higher affinity for di-and tri-peptides over single amino acids,44 
therefore, the pseudo tripeptide Ala-Ala-ciprofloxacin conjugate 38 was synthesised to 
target these transporters. The peptide was directly attached to the nitrogen of the 
piperazine ring of ciprofloxacin as this is not part of the pharmacophore.11 The proposed 
synthesis of conjugate 38 is outlined in Scheme 3.  
2.1.1. Methylation of ciprofloxacin 
              The first step towards the synthesis of 38 was the methylation of ciprofloxacin to 
protect the carboxylic acid group and remove the zwitterionic character of ciprofloxacin, 
improving its solubility profile in organic solvents.23  
 
Scheme 4: Methylation of ciprofloxacin 
              Ciprofloxacin methanoate 41 was successfully synthesised from commercially 
available ciprofloxacin, in 94% yield. The successful synthesis was supported by mass 
spectrometric analysis with a peak at m/z 346.15 present in the spectrum corresponding 
to [M+H]+ C18H21FN3O3. In addition 
1H NMR spectroscopic analysis showed a singlet at 
3.84 ppm with a relative integration of three corresponding to the methyl group, the 13C 
NMR spectrum showed a peak at 51.63 ppm confirming the presence of an added 
methyl group on 41.  
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Scheme 3: The proposed synthesis of conjugate 38  
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2.1.2. Conjugation of Boc-Ala-Ala-OH to methyl-ciprofloxacin 41 
              Methyl-ciprofloxacin 41 was coupled to Boc-protected di-alanine (Boc-Ala-Ala-
OH) 42 using EDC-mediated coupling (Scheme 5).55,56   
 
Scheme 5: Coupling of Boc-Ala-Ala-OH to 41 
              Conjugate 43 was isolated in 43% yield by column chromatography. The 
successful synthesis of 43 was supported by mass spectrometric analysis with a peak at 
m/z 588.28 present in the spectra corresponding to [M+H]+ C29H39FN5O7. 
1H NMR 
spectroscopy showed a singlet at 3.83 ppm (s, 3H relative integration) in the spectrum 
which corresponds to the ester methyl group of ciprofloxacin and an additional singlet at 
1.38 ppm (s, 9H relative integration)  corresponding to the methyl group of the t-butyl 
group. In addition, the spectrum revealed peaks at 1.32 ppm (m, 6H relative integration) 
corresponding to the two methyl side chains on Ala-Ala , 4.90 ppm (m, 1H relative 
integration) and 4.18 ppm (m, 1H relative integration) these correspond to the two α – 
CH groups of the peptide. The assignment of the two peaks (4.90 ppm and 4.18 ppm) 
was supported by homonuclear correlation spectroscopy COSY below (Figure 35) 
showing the coupling of the α – CH protons with side chain methyl group. This coupling 
and the presence of ciprofloxacin protons in the spectrum strongly supports the 
structure of 43.    
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Figure 35: COSY spectrum showing coupling of Ala-Ala protons of 43 
              The successful synthesis of 43 was also supported by 13C NMR spectroscopy in 
which the spectrum showed peaks at 18.52 ppm corresponding to the two CH3 side 
chain groups of the peptide, 28.13 ppm corresponding to the methyl groups of the t-
butyl and a peak at 51.81 ppm corresponding to the methyl ester of ciprofloxacin.  
 
2.1.3. Deprotection of conjugate 43 
              Removal of the t-butyloxycarbonyl protecting group was performed first 
(Scheme 6) because it was discovered during synthesis of 28 that performing methyl-
deprotection first leads to solubility issues (unpublished results). Conjugate 43 was 
hydrolysed to the TFA salt using 20% TFA in dry DCM57.  
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Scheme 6: Deprotection of 43  
              The successful deprotection of 43 to give 44 was supported by mass 
spectrometric analysis with a peak at m/z 488.23 corresponding to [M+H]+ C24H31FN5O5 
present in the spectrum. 1H NMR spectroscopic analysis also supported the successful 
synthesis of 44 as the singlet at 1.38 ppm (s, 9H relative integration) which corresponds 
to the t-butyloxycarbonyl group protons absent from the spectrum. The 13C NMR 
spectrum also showed the absence of the three CH3 groups of the t-butyloxycarbonyl at 
28.13 ppm.  
              The deprotection of the methyl ester by base hydrolysis was done with 1M HCl 
to neutralise the sodium carboxylate and reveal the carboxylic acid in 45. Successful 
synthesis of 45 was supported by 1H NMR spectroscopy which showed the absence of 
the singlet at 3.83 ppm (s, 3H relative integration) in the spectrum. In addition the 13C 
NMR spectrum showed the absence of a peak at 51.81 ppm and mass spectrometric 
analysis gave a spectrum with a peak at m/z 464. 21 corresponding to [M+H]+ 
C23H29FN5O5. The 
19F NMR spectroscopy showed a peak at -76.76 ppm corresponding to 
the trifluroacetate and a peak at -126.76 ppm corresponding to the aromatic fluorine of 
ciprofloxacin.  
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2.1.4. Counter-ion exchange  
              Trifluoroacetate salts are known to perturb in vivo studies,58 therefore counter-
ion exchange of trifluroacetate by another acid is desirable. The procedure of freeze-
drying the peptide several times in the presence of HCl to directly replace the 
trifluroacetate counter ion with chloride ion59 was applied to conjugate 45 and 28.  
 
Scheme 7: Counter ion exchange of conjugate 45 
             The successful synthesis of 38 was supported by 19F NMR which showed only one 
peak at -126.78 ppm corresponding to the aromatic fluorine of ciprofloxacin and the 
fluorine trifluroacetate peak at -76.76 ppm was not observed in the spectrum. 
             Successful synthesis was also supported by mass spectrometric analysis with the 
product peak at m/z 464.21 corresponding to [M+H]+ C23H29FN5O5 present in the mass 
spectrum.  
Scheme 8: Counter ion exchange of conjugate 28 
              Compound 28 was subjected to the same counter ion exchange and the 
successful synthesis of conjugate 46 was supported by 19F NMR spectroscopic analysis 
showed one peak at -126.76 ppm corresponding to the ciprofloxacin fluorine and no 
peak observed at -76.76 ppm in the spectrum indicating the successful removal of 
trifluroacetate. The mass spectrometric analysis showed a peak at m/z 403.18 which 
corresponds to [M+H]+ C20H24FN4O4 present in the spectrum. 
2.2. Synthesis of ciprofloxacin-disulfide-Ala conjugate 39 
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              In the design of the biolabile ciprofloxacin conjugates, 2,2’-dithiodiethanol 48 
was used in order to release ciprofloxacin in the bacterial cytoplasm. Disulfide 48 was 
conjugated to the carboxylic group of ciprofloxacin, although this functional group is 
essential for antimicrobial activity11 cleavage of the biolabile linker within the cytoplasm 
will reveal the ciprofloxacin carboxylic group (Scheme 2). Conjugation to the carboxylic 
acid group also results in a conjugate/-prodrug with a net positive charge allowing 
favourable interaction with highly anionic LPS on the surface of the bacterial outer 
membrane.6 
              Alanine (Ala) was used as a control for the synthetic approach allowing testing 
the chemistry. It was unlikely that conjugation of a single amino acid would allow the 
conjugate to be actively transported as it has been reported that PTR secondary active 
transporters have higher affinity for di-and tri-peptides over single amino acids.44 The 
proposed synthesis of ciprofloxacin-disulfide-Ala 39 is shown in Scheme 9. 
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Scheme 9: Proposed synthesis of ciprofloxacin-disulfide-Ala 39 
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2.2.1. Disulfide conjugation  
              The conjugation of 2,2’-dithiodiethanol 48 to commercially available 
ciprofloxacin was initially attempted using thionyl chloride to make acid chloride 47 
(Scheme 10).60 A solubility scan of ciprofloxacin in a range of solvents was carried out 
and it was found to be insoluble in all solvents tested; polar and non-polar, however, it 
was slightly soluble in DCM therefore DCM was used in the synthesis (Scheme 10). It was 
noted that previous successful esterification reactions of ciprofloxacin in the presence of 
thionyl chloride were possible when the alcohol used for esterification was also used as 
the reaction solvent.60 This approach was discounted in the synthesis of 49 as 2,2’-
dithiodiethanol would be required as the solvent, with considerable waste and expense. 
 
 
Scheme 10: The esterification of ciprofloxacin in the presence of thionyl chloride 
             The synthesis of 49 was found to be unsuccessful, by both mass spectrometric 
and 1H NMR spectroscopic analysis of the crude reaction in spite of the reaction being 
carried out under anhydrous conditions as the reactive intermediate 47 is moisture 
sensitive.61 However, as the acid chloride 47 was not isolated, the synthesis of the acid 
chloride intermediate could not be confirmed. 
              A second synthesis of 49 was attempted with the addition of DMF (1.29mM) as a 
catalyst was carried out. The use of DMF as a catalyst in the presence of thionyl chloride 
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was adapted from the preparation of an acid chloride using oxalyl chloride and DMF.53,62 
It is believed that DMF reacts with thionyl chloride to give the Vilsmeier-Haack reagent 
which will then react with the carboxylic acid forming the reactive acid chloride63 
(Scheme 11). However no evidence of the desired product 49 was observed by mass 
spectrometric or 1H NMR spectroscopic analysis. 
 
Scheme 11: DMF-catalysed synthesis of carboxylic chloride in the presence of thionyl 
chloride 
                           As the solubility of ciprofloxacin was limited in organic solvents. One 
approach to enhance reactivity was to increase the solubility profile of ciprofloxacin; 
therefore the piperazinyl nitrogen group was Boc-protected removing the zwitterionic 
character of ciprofloxacin as shown in scheme 12. 
 
 
 
 
 
 
2.2.1.1. Boc-protection of ciprofloxacin    
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              Commercially available ciprofloxacin (1eqv) was reacted with Boc anhydride 
(2eqv) in the presence of 1M NaOH dissolved in a solution of dioxane:water (1:1) 
(Scheme 12).  
Scheme 12: Synthesis of Boc-protected ciprofloxacin 50 
             Protected ciprofloxacin 50 was isolated in 94% yield and the successful synthesis 
of 50 was supported by mass spectrometric analysis with a peak at m/z 454.17 evident 
in the spectrum corresponding to [M+Na]+ C22H26FN3NaO5 and also by 
1H NMR 
spectroscopic analysis as the spectrum showed a signal at 1.48 (s, 9H) corresponding to 
the three methyl groups on the t-butyloxycarbonyl protecting group.  
              Although the Boc-group enhances the solubility of ciprofloxacin it also prohibits 
the esterification of 50 using thionyl chloride because an acid, HCl, is produced as a by-
product of the reaction and the Boc-protected amine is acid labile.62 As a result of this 
incompatibility alternative esterification methods were explored. 
2.2.1.2. Dicyclohexylcarbodiimide (DCC) – mediated esterification 
              DCC has frequently and successfully been used for the synthesis of amino acid 
derivatives and has also been adopted as a method for the preparation of esters.62 The 
addition of 4-dimethylaminopyridine (DMAP) has been proved to significantly accelerate 
DCC-activated esterification of carboxylic acids with alcohols.64 Therefore DCC/DMAP 
mediated esterification was carried out in order to synthesise Boc-protected 
ciprofloxacin – 2,2’-dithiodiethanol conjugate 51 (Scheme 13).  
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 Scheme 13: Synthesis of boc-protected ciprofloxacin-2,2’-dithiodiethanol 51 
              The attempted synthesis of 51 using DCC/DMAP method was repeated several 
times with no evidence of the coupled product. A few modifications were applied to the 
experimental procedure on each repeat, with the original procedure being based on the 
method adapted from Jain et al.53 Some modifications included incremental changes in 
the molar ratios of DCC and DMAP in order to facilitate the activation of 50 and also 
carrying out the reaction under anhydrous conditions so as to avoid any side reactions 
with water. 
Run 
Number 
Boc-cip 50 / mmol DCC / mmol DMAP / mmol Other Reaction 
Modification 
1 0.36 0.36 0.36 THF 
2 0.46 0.46 0.46 DMF 
3 0.46 0.60 0.60 dry DCM 
4 0.46 0.60 0.60 dry DCM, stepwise 
 
Table 1: Table showing the modifications of the reaction conditions for the esterification 
of Boc-protected ciprofloxacin 50 using DCC/DMAP method 
              Another modification whereby reagents were added stepwise (run 4) to allow 
analysis of the activated intermediates was carried out. The active O-acylisourea 
intermediate often undergoes acetyl transfer forming the unreactive N-acylurea.62 This 
competes with the forward esterification reaction which is catalysed by DMAP as shown 
in Scheme 14. 
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Scheme 14: Rearrangement and esterification of O-acylisourea 
              The unsuccessful esterification of 50 was thought to be due to rearrangement of 
O-acylisourea to unreactive N-acylurea. However this was found to be not the case as no 
evidence of either the O-acylisourea or N-acylurea was found by mass spectrometric 
analysis of the crude reaction mixture. A peak at m/z of 454.17 was evident in the 
spectrum, this corresponds to unreacted 50 (C22H26FN3NaO5). Therefore it was 
concluded that there was no activation of 50 using the DCC/DMAP method and 
alternative methods were explored. 
 
2.2.1.3. NHS/DCC – mediated esterification 
              An alternative activation method was explored using N-hydroxysuccinimide 
(NHS) and DCC as an activating agents.65 
 
 
 
59 
 
 Scheme 15: Synthesis of 51 using DCC and NHS as activating agents 
              However, the synthesis was not successful as no evidence for the coupled 
product was observed either by mass spectrometric analysis or 1H NMR spectroscopy of 
the crude reaction mixture. It was then decided to change the reactant ratios to 
1:1.5:1.5 (Boc-ciprofloxacin: NHS:  DCC) so as to increase the chances of the activation of 
50. The reaction was also carried out stepwise to allow isolation and analysis of the 
ciprofloxacin-NHS ester as shown below (Scheme 16). 
 Scheme 16: Stepwise activation of Boc-ciprofloxacin with DCC and NHS 
              There was no visible change to the reaction mixture by observation or by TLC 
analysis and also mass spectrometric analysis did not show peaks relating to successful 
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product formation. Regardless of the unsuccessful isolation of the intermediates the 
reaction was continued by adding the 2,2’-dithiodiethanol 48 to the reaction mixture as 
the intermediates might not be stable enough to be isolated. However there was no 
evidence of 51 either by mass spectrometric or 1H NMR spectroscopic analysis. 
              A control experiment was carried out in order to test the DCC/DMAP chemistry. 
Nicotinic acid 52 and 2,2’-dithiodiethanol 48 were used in the synthesis of nicotinic acid- 
2,2’-dithiodiethanol 53 using an experimental procedure adapted from Jain et al53 
(Scheme 17). 
 Scheme 17: Synthesis of nicotinic acid-2,2’-dithiodiethanol 53 
              The synthesis of 53 was successful by mass spectrometric analysis of the crude 
product. Peaks at m/z 260.04 and m/z 365.06 were observed in the mass spectrum, 
corresponding to [M+H]+ C10H14NO3S2  and [2M+H]
+ C16H17N2O4S2 respectively.  
This indicated the DCC/DMAP method is a viable method for esterification but it had 
proved unsuccessful with Boc-protected ciprofloxacin 50. 
               It was then decided to explore alternative coupling reagents. Uronium salts such 
as HBTU and HATU have been found to be efficient peptide coupling reagents66 
therefore these agents were used in the esterification of Boc-protected ciprofloxacin 50 
with disulfide 48. 
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2.2.1.4. HBTU and HATU – mediated esterification 
Scheme 18: Synthesis of 51. Reagents and conditions: (a) HBTU, DMAP, DIPEA, dry DCM; 
(b) HATU, DMAP, DIPEA, dry DCM 
              The successful synthesis of 51 using either reagents a or b was supported by 
mass spectrometric analysis of the crude reaction mixture, in both reactions the mass 
spectra showed peaks for both the monomer and dimer at m/z 590.17 and 1003.35 
which correspond to [M+Na]+ and [2M+Na]+ respectively. However the purification 
process was problematic due to co-elution with possibly the dimer during column 
chromatography and 51 was unable to be isolated to allow further characterisation. 
              Although both HBTU and HATU proved to be successful in performing the 
coupling between 50 and 48, HATU was found to be more efficient of the two as the 
reaction time was significantly shorter although the yields were not evaluated at this 
stage due to problematic isolation. Looking at peptide coupling with HATU and HBTU, 
HATU shows enhanced reactivity towards amines relative to that of HBTU66. This is 
thought to be due to the effect of the neighbouring group on the intermediate as shown 
in Figure 36, with HATU an active ester intermediate is formed which is not possible 
when HBTU is used66 therefore this could potentially be the reason for the observed 
faster reaction time with HATU. 
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Figure 36. Intermediate structures of HBTU and HATU during peptide coupling 
 
              Since the purification of 51 was problematic it was decided to couple Boc-
ciprofloxacin with a protected 2,2’-dithiodiethanol 54 (Scheme 19) aiming to change the 
polarity of the desired product 55 in order to obtain a better separation when using 
column chromatography. 
 
Scheme 19: The synthesis of conjugate 55 
              Mono ester protected 2,2’-dithiodiethanol was synthesised and although the 
isolated yield of 54 was poor,26% , the successful synthesis of 54 was supported by mass 
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spectrometric analysis with a peak of m/z 219.01 corresponding to [M+Na]+ present in 
the spectrum, 1H NMR spectroscopic analysis showed the presence of a signal at 2.09 
ppm (s, 3H) corresponding to the methyl group. 
              The protected disulfide 54 was then used in the HATU-mediated coupling with 
Boc-protected ciprofloxacin 50. The successful synthesis of conjugate 55 was supported 
by mass spectrometric analysis with inspection of the spectrum revealing a peak at m/z 
of 632.19 [M+Na]+, 1H NMR spectroscopic analysis showed signals corresponding to the 
product; 1.41 ppm (s, 9H relative integration) of the Boc-protecting group and 1.98 ppm 
(s, 3H relative integration) corresponding to the acetate protecting group. 13C NMR 
spectroscopic analysis showed the presence of three quaternary carbon signals at 
170.28 ppm, 165.21ppm, and 164.17ppm. Analysis of the crude mixture strongly 
suggested that 55 was the main component of the reaction. However purification still 
proved to be problematic resulting in a poor 34% isolated yield of 55.  
              Although conjugate 55 was synthesised successfully albeit in low yield, there was 
an additional problem, the removal of the methyl ester could result in the hydrolysis of 
the ester bond between 50 and 54. Therefore it was decided that crude 51 could be 
further elaborated without purification, delaying a purification step to later in the 
synthesis. 
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2.2.2. Conjugation of alanine 
              Commercially available Boc-Ala 56 was coupled to crude 51 using a method 
adapted from Dhaon et al. for the esterification of N-protected α-amino acids.67 The 
successful synthesis of 57 was supported by mass spectrometric analysis, 1H NMR, 13C 
NMR spectroscopy and IR analysis.  
 
 Scheme 20: The synthesis of conjugate 57 using EDC  
              The mass spectrum showed a peak at m/z of 761.27 which corresponds to 
[M+Na]+, the 1H NMR spectrum showed the presence of two Boc-groups with signals at 
1.48 ppm (s, 9H relative integration), 1.42 ppm (s, 9H relative integration) and also 
multiplets corresponding to the disulfide backbone 2.82 ppm (m, 2H relative 
integration), 2.90 ppm (m, 2H relative integration) and 4.29 – 4.36 ppm (m, 4H relative 
integration). The connectivity was probed by two dimensional NMR spectroscopy.  
              The homonuclear correlation spectroscopy (COSY) shown below showed the 
expected coupling between the alanine methyl side chain and the α – hydrogen and the 
disulfide backbone protons strongly supporting the structure of 57 (Figure 37). 13C NMR 
showed three quaternary carbon signals at 172.69 ppm, 172.15 ppm and 164.02 ppm 
also two signals at 27.87 ppm and 27.94 ppm corresponding to the Boc-groups, in 
addition IR spectroscopy showed the presence of N-H amide stretch at 3301 cm-1. 
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Figure 37: COSY NMR spectrum of 57 showing the coupling between the disulfide 
backbone protons (purple dotted lines) and coupling between the side chain methyl 
group and the α – CH (green dotted lines) 
2.2.3. Deprotection of conjugate 57 
              Conjugate 57 has Boc protecting groups at both ends of the conjugate, therefore 
a global Boc-deprotection using 20%TFA in dry DCM to produce conjugate 58 was 
undertaken as shown in Scheme 21. 
 
Scheme 21: The deprotection of conjugate 57 
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              The successful synthesis of conjugate 58 was supported by; mass spectrometric 
analysis which showed a peak with an m/z of 270.09 [M]2+ C24H33FN4O5S2 present in the 
spectrum, 1H NMR spectrum supported the successful deprotection as signals at 1.42 
ppm  and 1.48 ppm corresponding to the t-butyloxycarbonyl group protons were not 
present in the spectrum and 13C NMR spectrum showed only two quaternary carbon 
signals at 171.10 ppm and 167.35 ppm with no signals for the t-butyloxycarbonyl groups.  
2.2.4. Counter - ion exchange of 58 
              As mentioned in Section 2.1.4. TFA salts are known to perturb in vivo studies58 
therefore the trifluroacetate was exchanged with a more bio-compatible ion, chloride. 
 
Scheme 22: Counter ion exchange of conjugate 58 
              The successful synthesis of 39 was supported by 19F NMR spectroscopic analysis 
which showed one peak at -122.29 ppm corresponding to the ciprofloxacin fluorine and 
no peak was observed at -76.76 ppm confirming the successful removal of 
trifluroacetate. The mass spectrometric analysis showed a peak at m/z 270.09 
corresponding to [M]2+ C24H33FN4O5S2 present in the spectrum. 
              The successful synthesis of 39 showed the chemistry to be reliable therefore 
ciprofloxacin-disulfide-diAla 40 was synthesised using the same synthetic procedures 
developed in Section 2.3. 
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2.3. Synthesis of ciprofloxacin-disulfide-diAla conjugate 40 
             The dipeptide Ala-Ala was used a nutrient as it has been observed that the PTR 
secondary active transporters have higher affinity for di-and tri-peptides over single 
amino acids.44 Therefore, ciprofloxacin-disulfide-diAla 40 was synthesised to exploit the 
PTR secondary active transporters so as to actively transport the conjugate across the 
bacterial inner membrane. The proposed synthesis of 40 is shown Scheme 23. 
Scheme 23: The proposed synthesis of 40 
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2.3.1. Conjugation of boc-diAla 59 to boc-ciprofloxacin-2,2’-dithiodiethanol 52 
              Boc-diAla 59 was coupled to crude Boc-ciprofloxacin-2,2’-dithiodiethanol 52 
using the same synthetic procedure in Section 2.2.1.5. adapted from Dhaon et al.67 
 
Scheme 24: The synthesis of 60 using EDC and DMAP coupling agents 
              The successful synthesis of 60 was supported by mass spectrometric, 1H NMR 
spectroscopic and 13C NMR spectroscopic analysis. Mass spectrometric analysis showed 
a peak with an m/z of 832.31 corresponding to [M+Na]+, the 1H NMR spectrum showed a 
multiplet at 1.33 ppm (5H relative integration) corresponding to 5H of the two CH3 side 
chains of the dipeptide with the remaining proton incooperated into the peak at 1.41 
ppm (10H relative integration) which corresponds to the 9H of one of the t-
butyloxycarbonyl groups. A peak for the other t-butyloxycarbonyl group was observed at 
1.47 ppm (9H relative integration). Disulfide backbone protons were also observed at 
2.94 ppm (m, 2H relative integration), 3.04 ppm (m, 2H relative integration), 4.35-4.54 
ppm (m, 5H relative integration) which incooperated one of the α – CH protons with the 
other α – CH observed at 4.21 ppm (m, 1H). COSY spectroscopy (Figure 38) showed the 
expected coupling in the peptide and disulfide therefore the structure of 60 was strongly 
supported by the 1H spectroscopic evidence.  
              13C NMR spectrum showed the presence of two t-butyloxycarbonyl with peaks at 
27.91 ppm and 28.01 ppm corresponding to the methyl groups and peaks for the 
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peptide CH3 side chain groups were also observed at 17.63 ppm, In addition four 
quaternary carbon signals were also observed. 
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Figure 38: COSY NMR of 60 showing the coupling between disulfide backbone protons 
(purple dotted lines) and coupling between the side chain methyl groups and the α – CH 
(green dotted lines) 
2.3.2. Deprotection of 60 
              The t-butyloxycarbonyl protecting groups on conjugate 60 were removed using 
the 20%TFA in dry DCM to produce 61. 
 
Scheme 25: Deprotection of conjugate 60 
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              The successful synthesis of conjugate 61 was supported by; mass spectrometric 
analysis which showed a peak with an m/z of 305.61 [M]2+ C27H38FN5O6S2 present in the 
spectrum. In addition, 1H NMR spectroscopic analysis showed the signals at 1.41 ppm 
and 1.47 ppm corresponding to the t-butyloxycarbonyl group protons were not absent 
from the spectrum. In addition the 13C NMR spectrum showed only three quaternary 
carbon signals at 174.06 ppm, 170.60 ppm and 163.23 ppm with no signals for the t-
butyloxycarbonyl groups observed. 
2.3.3. Counter - ion exchange of 61 
              Trifluroacetate was exchanged with a more bio-compatible ion, chloride, by 
freeze-drying conjugate 61 with 10 mM HCl. 
 
Scheme 26: Counter - ion exchange of conjugate 61 
              The successful ion exchange in 40 was supported by 19F NMR spectroscopic 
analysis which showed one peak at -122.82 ppm corresponding to the ciprofloxacin 
fluorine and no peak was observed at -76.75 ppm confirming the successful removal of 
trifluroacetate. The mass spectrometric analysis showed a peak at m/z 305.61 [M]2+ 
C27H38FN5O6S2 present in the spectrum.  
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2.4. Biological screening of conjugate 38 and 46 
Figure 39: Structures of conjugate 38 and 46 
              Conjugate 38 was tested for antibacterial activity against E. coli with a direct 
comparison to 46 since 28 (in its non-counter ion exchanged form) was shown to retain 
antimicrobial activity but at a lower level than ciprofloxacin (unpublished results). TFA 
acetate was used as a control in-order to determine if antimicrobial activity observed for 
conjugate 28 was due to the trifluroacetate.58 
               In vivo assays were carried out at different concentrations in lysogenic broth 
(LB) using sterile techniques to prepare a 96 well plate with the layout outlined in Table 
2.       
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1 2 3 4 5 6 7 8 9 10 11 12 
A                       
B TFA(1) TFA(2) TFA(3) 
Cip-
Ala(1) 
Cip-
Ala(2) 
Cip-
Ala(3) 
Cip-
diAla(1) 
Cip-
diAla(2) 
Cip-
diAla(3) Blank   
C TFA(1) TFA(2) TFA(3) 
Cip-
Ala(1) 
Cip-
Ala(2) 
Cip-
Ala(3) 
Cip-
diAla(1) 
Cip-
diAla(2) 
Cip-
diAla(3) Blank   
D TFA(1) TFA(2) TFA(3) 
Cip-
Ala(1) 
Cip-
Ala(2) 
Cip-
Ala(3) 
Cip-
diAla(1) 
Cip-
diAla(2) 
Cip-
diAla(3) Blank   
E TFA(1) TFA(2) TFA(3) 
Cip-
Ala(1) 
Cip-
Ala(2) 
Cip-
Ala(3) 
Cip-
diAla(1) 
Cip-
diAla(2) 
Cip-
diAla(3) Blank   
F TFA(1) TFA(2) TFA(3) 
Cip-
Ala(1) 
Cip-
Ala(2) 
Cip-
Ala(3) 
Cip-
diAla(1) 
Cip-
diAla(2) 
Cip-
diAla(3) Blank   
G TFA(1) TFA(2) TFA(3) 
Cip-
Ala(1) 
Cip-
Ala(2) 
Cip-
Ala(3) 
Cip-
diAla(1) 
Cip-
diAla(2) 
Cip-
diAla(3) Blank   
H                       
 
                                                                  Key:  
                                                             TFA = Trifluroacetate 
                                              Cip-Ala = 46 
 
                
Cip-diAla = 38 
 
Table 2: 96 - well plate layout for in vivo plate reader assay with triple replicates of each 
antibiotic; cip-Ala 46 and cip-diAla 38 and trifluroacetate. Row B is a control with 0μM 
drug concentration; rows C-G are wells with increasing drug concentration, blank wells 
in column 11 and sterile water in the surrounding wells 
               
              E. coli was grown for 16 hours and absorbance (OD) was measured every 30 
minutes to generate growth curves with trifluroacetate as a control. Figure 40 shows 
that under control conditions; when no conjugate or trifluroacetate present, WT E. coli 
BW25113 strain reaches a peak OD650 of ~ 3 after about 11 hours. 
Drug conc/ 
μM  
Stock conc/ 
μM 
0.0 0 
2.0 10 
4.0 20 
6.0 30 
8.0 40 
10 50 
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Figure 40: Control bacterial growth curve of BW25113 strain of E. coli. Error bars are ± 
standard deviation of three biological replicates 
              Adding 2.0 μM of trifluroacetate and cip-diAla 38 did not have any significant 
effect on the bacterial growth as a maximum OD650 of ~ 2.8 was reached after 8 hours 
(Figure 41A) which is not substantially different from the maximum OD650 ~ 3 reached 
under control conditions (Figure 40).  
              However, a difference in bacterial growth was observed with cip-Ala 46 at 2.0 
μM, reaching a maximum OD650 of ~ 0.6 after 5 hours and almost complete bacterial 
growth inhibition after 12 hours (Figure 41A). This suggests that for 46 MIC ˃ 0.0 μM but 
≤ 2.0 μM, it also shows that the antimicrobial activity observed for 28, the TFA salt of 
cip-Ala, was not due to the presence of trifluroacetate since no observable inhibition of 
bacterial growth was observed with trifluroacetate at this concentration.   
              These results indicate that 46 is a more effective bacterial growth inhibitor than  
38, suggesting that 38 is not being actively transported but probably entering the 
bacterial inner membrane by passive diffusion. The reduction in antimicrobial activity of 
38 could also be due to the presence of the nutrient moiety as it has been suggested 
that a group on the piperazinyl nitrogen significantly reduces the ability of the 
fluoroquinolone to interact with DNA gyrase therefore leading to incomplete 
inhibition30,29 and lower antimicrobial activity.   
              Increasing the concentration from 2.0 μM to 4.0 μM (Figure 41B) showed 
reduction in bacterial growth with 38 reaching a peak OD650 of ~ 2.0 after 5 hours and a 
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minimum OD650 of ~ 0.9 after 16 hours. This significant reduction in bacterial growth 
suggests that the MIC for 38 is between 2.0 μM and 4.0 μΜ. Cip-Ala 46 had increased 
antimicrobial activity at 4.0 μM with almost complete bacterial growth inhibition after 9 
hours as opposed to after 12 hours at 2.0 μM. 
 
 
Figure 41: Bacterial growth curve of E. coli BW25113 with 2.0 μM (A) and 4.0 μM (B) 
additives. Error bars are ± standard deviation of three biological replicates 
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                           Further increase in concentration to 6.0 μM (Figure 42A), 8.0 μM (Figure 
42B) and 10.0 μM (Figure 42C) had a significant increase on the antimicrobial activity of 
cip-diAla 38, little effect on the antimicrobial activity of cip-Ala 46. 
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Figure 42: Bacterial growth curve of E. coli BW25113 grown with 6.0 μM (A), 8.0 μM (B) 
and 10.0 μM (C) additives. Error bars are ± standard deviation of three biological 
replicates 
   
              These results show that conjugate 38 has significantly reduced activity against E. 
coli BW25113 compared to 46 at the same concentration. This reduction has been 
suggested to be due to the nutrient moiety at the piperazinyl nitrogen which 
significantly reduces the ability of the fluoroquinolone to interact with DNA gyrase 
therefore leading to incomplete inhibition with diAla having a larger effect than Ala. 
               In-order to determine the effect of conjugating a di-peptide on the gyrase 
inhibitory activity of ciprofloxacin in-vitro DNA gyrase experiments were performed with 
ciprofloxacin as a control.  
 
2.4.1. DNA gyrase assays 
               Gyrase assays show the DNA gyrase inhibition ability of the compounds, with 
the presence of relaxed plasmid on the gyrase indicating the inhibition of DNA gyrase 
whereas supercoiled plasmid indicates the activity of DNA gyrase therefore the 
compound has reduced activity or is inactive. Relaxed pBR322 open complex bacterial 
plasmid was incubated with E. coli DNA gyrase at variable concentrations of ciprofloxacin 
or cip-diAla 38 to investigate any changes in the DNA gyrase’s ability to supercoil relaxed 
DNA at relatively low and high concentrations. 
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Table 3: Tables showing the concentration of antibiotics used for each assay 
 
 
 
Figure 43: DNA gyrase assay of ciprofloxacin (A) and cip-diAla 38 (B) at different 
concentrations with positive control (+ve) – 2 μl DNA gyrase and 0.0 μM of drug, 
negative control (-ve) – no DNA gyrase and 0.0 μM of drug and an empty well (gap). OC- 
open circular and SC- supercoiled plasmid 
Cip-diAla 
Stock conc/ 
μM 
Drug conc/  
μM 
200 6 
400 13 
600 20 
800 27 
1000 33 
Ciprofloxacin 
Stock conc/ 
μM 
Drug conc/ 
μM 
3 0.1 
6 0.2 
9 0.3 
12 0.4 
15 0.5 
+ve 
 
-ve gap 0.1μM 0.2μM 0.3μM 0.4μM 0.5μM 
OC 
SC 
A 
+ve 
 
-ve gap 6.0μM 13μM 20μM 27μM 33μM B 
OC 
SC 
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               Treatment of relaxed pBR322 with DNA gyrase converts the relaxed plasmid to 
the supercoiled plasmid which migrates faster on  agarose gel as observed with the +ve 
control (Figure 43), an open circular plasmid is present in the relaxed plasmid and it co-
migrates with some of the relaxed plasmid as observed with the –ve control (Figure 43).  
              Very little inhibition of DNA gyrase was observed between 0.1 μM and 0.3 μM of 
ciprofloxacin (Figure 43A) as the supercoiled bands were still present but also thick open 
complex bands were observed, as the concentration was increased to 0.4 μM significant 
inhibition of DNA gyrase was observed with more relaxed plasmid bands and a faint 
supercoiled band across the agarose gel. At 0.5 μM of ciprofloxacin, (Figure 43A) very 
faint relaxed plasmid bands were observed and no supercoil bands present, this could be 
due to pipetting error with not enough sample added to the well.  
              Cip-diAla 38 showed some gyrase inhibition between 6.0 μM and 20μM as both 
relaxed plasmid bands and supercoiled bands were observed (Figure 43B). However the 
intensity of the bands is similar at these three concentrations suggesting that the gyrase 
inhibitory activity of cip-diAla is not increasing with concentration. At 27μM no 
supercoiled band is observed but at 33 μM the band is present (Figure 43B) suggesting 
that the absence of the supercoiled band at 27 μM could have been due to pipetting 
error and not due to gyrase inhibition by cip-diAla.  
              Cip-diAla 38 has significantly reduced activity against E. coli DNA gyrase 
compared to that of ciprofloxacin, considering that at relatively high concentration of 
cip-diAla (20 μM) the supercoiled band is still present therefore cip-diAla does not 
completely inhibit DNA gyrase at this concentration. However, according to the in vivo 
assays of cip-diAla 38 (Figure 42C) cip-diAla almost completely inhibits bacterial growth 
of BW25113 strain of E. coli at 10.0 μM after about 15 hours. It has been reported that 
the MIC for intact bacteria can be much lower than the concentrations required to 
inhibit the gyrase from the same organism15 therefore more gyrase assays at different 
concentrations of cip-diAla will need to be carried out in-order to compare the MIC and 
Ki (inhibition constant) of cip-diAla in E. coli. 
              It can be concluded from these results that the conjugate diAla significantly 
interferes with the inhibition of DNA gyrase therefore causing reduction in the activity of 
cip-diAla 38. This may be due to the additional steric bulk which may be preventing the 
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effective formation of the DNA-enzyme-drug complex (Figure 12) which is critical for the 
activity of fluoroquinolones.20 Therefore ciprofloxacin conjugates 39 and 40 with a bio-
labile linker which allows the release of free ciprofloxacin within the bacterial inner 
membrane were synthesised.   
 
2.5. Biological screening of conjugate 39 and 40 
Figure 44: Structures of conjugate 39 and 40 
              In vivo assays of conjugate 39 and 40 against E. coli BW25113 to test if the novel 
bio-labile linked compounds had increased antimicrobial activity compared to free 
ciprofloxacin as the conjugates are proposed to be actively transported by peptide 
transporters. The in vivo assays were carried out at different concentrations in LB using 
sterile techniques to prepare a 96 well plate with the layout outlined in Table 4. 
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1 2 3 4 5 6 7 8 9 10 11 12 
A                       
B Cip(1) Cip(2) Cip(3) 
Cip-
link-
Ala(1) 
Cip-
link-
Ala(2) 
Cip-
link-
Ala(3) 
Cip-
link-
diAla(1) 
Cip-
link-
diAla(2) 
Cip-
link-
diAla(3) Blank   
C Cip(1) Cip(2) Cip(3) 
Cip-
link-
Ala(1) 
Cip-
link-
Ala(2) 
Cip-
link-
Ala(3) 
Cip-
link-
diAla(1) 
Cip-
link-
diAla(2) 
Cip-
link-
diAla(3) Blank   
D Cip(1) Cip(2) Cip(3) 
Cip-
link-
Ala(1) 
Cip-
link-
Ala(2) 
Cip-
link-
Ala(3) 
Cip-
link-
diAla(1) 
Cip-
link-
diAla(2) 
Cip-
link-
diAla(3) Blank   
E Cip(1) Cip(2) Cip(3) 
Cip-
link-
Ala(1) 
Cip-
link-
Ala(2) 
Cip-
link-
Ala(3) 
Cip-
link-
diAla(1) 
Cip-
link-
diAla(2) 
Cip-
link-
diAla(3) Blank   
F Cip(1) Cip(2) Cip(3) 
Cip-
link-
Ala(1) 
Cip-
link-
Ala(2) 
Cip-
link-
Ala(3) 
Cip-
link-
diAla(1) 
Cip-
link-
diAla(2) 
Cip-
link-
diAla(3) Blank   
G Cip(1) Cip(2) Cip(3) 
Cip-
link-
Ala(1) 
Cip-
link-
Ala(2) 
Cip-
link-
Ala(3) 
Cip-
link-
diAla(1) 
Cip-
link-
diAla(2) 
Cip-
link-
diAla(3) Blank   
H                       
 
                         Key:  
                                                                     Cip = ciprofloxacin                                                   
                                                                  Cip-link-Ala = 39 
 
                      
Cip-link-diAla = 40 
 
Table 4: 96 - well plate layout for in vivo plate reader assay with triple replicates of each 
antibiotic; cip, cip-link-Ala 39 and cip-link-diAla 40. Row B is a control with 0 μM drug 
concentration; rows C-G are wells with increasing drug concentration, blank wells in 
column 11 and sterile water in the surrounding wells 
              E. coli was grown for 16 hours and absorbance (OD) was measured every 30 
minutes to generate growth curves with trifluroacetate as a control. Figure 45 shows 
that under control conditions; when no conjugate or ciprofloxacin present, WT E. coli 
BW25113 strain reaches a peak OD650 of ~ 3 after about 11 hours. 
Drug conc / 
μM 
Stock conc / 
μM 
0 0 
0.01 1 
0.1 10 
0.5 50 
1 100 
10 1000 (1mM) 
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Figure 45: Control bacterial growth curve of BW25113 strain of E. coli. Error bars are ± 
standard deviation of three biological replicates 
              Adding 0.01 μM of each drug did not have any observable effect on the growth 
of the bacteria as a maximum OD650 of ~ 3 was reached after 11 hours as shown in 
Figure 46A.  
              A difference in bacterial growth was observed after increasing the concentration 
of ciprofloxacin from 0.01 μM to 0.1 μM (Figure 46B), reduction in bacterial growth with 
a peak OD of ~ 1, this suggests that the MIC of ciprofloxacin is in the range of 0.01 μM to 
2.0 μM. 
             However, no difference in bacterial growth was observed with cip-link-Ala 39 and 
cip-link-diAla 40 (Figure 46B). This suggests that these conjugates are not effectively 
reaching their target at this concentration therefore no significant effect on bacterial 
growth is observed. 
             This result also rules out the hypothesis of the conjugates 39 and 40 being 
actively transported by primary or secondary peptide transporters as no bacterial 
growth inhibition was seen, whereas at the same concentration of 0.1 μM (Figure 46B), 
ciprofloxacin is showing significant inhibition and ciprofloxacin enters the cell through 
passive diffusion over a concentration gradient. This suggests that like ciprofloxacin the 
conjugates 39 and 40 are also transported by passive diffusion.  
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Figure 46: Bacterial growth curve of E. coli BW25113 grown with 0.01 μM (A) and 0.1 μM 
(B) additives. Error bars are ± standard deviation of three biological replicates 
 
               Reduction in bacterial growth was observed for all of the three drugs at 0.5 μM 
(Figure 47) with a significant reduction in bacterial growth observed for 39 and 40 
reaching a maximum OD of ~ 0.7 compared to OD of 3.0 at 0.1 μM (Figure 46B). This 
shows that these conjugates retained their antimicrobial activity although it does not 
exceed that of ciprofloxacin as a higher concentration of the conjugates (x5 fold) is 
required to obtain similar results to those of ciprofloxacin. However, no significant 
difference between the activity of 39 and 40 was observed (Figure 47). This result 
suggests that no active transport of the conjugates by peptide transporters is occurring 
as further bacterial growth reduction was expected to be observed with 40 due to the 
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higher affinity of secondary peptide transporters for dipeptides than single amino 
acids.44 
                This result supports the hypothesised intracellular cleavage of the disulfide 
linker, which suggests that the disulfide is reduced within the bacterial cytoplasm either 
by glutathione or cysteine releasing free ciprofloxacin, the peptide and other non-toxic 
compounds like CO2 (Scheme 2).  
 
Figure 47: Bacterial growth curve of E. coli BW25113 grown with 0.5 μM additives. Error 
bars are ± standard deviation of three biological replicates 
             A further reduction in bacterial growth was observed as the concentration was 
increased to 1.0 μM (Figure 48A) and 10 μM (Figure 48B) with almost complete 
inhibition by ciprofloxacin at 10 μM. Although the conjugates, 39 and 40, significantly 
inhibited growth at 10 μM, they did not completely inhibit it. This is thought to be due to 
inefficient thiol-induced cleavage of the disulfide bond in the bacterial cytoplasm and/or 
the disulfide bond can be cleaved but the formation of the 3-membered ring can be slow 
so mixed disulfides can be formed. The inefficient release of ciprofloxacin leads to 
reduced concentration of active ciprofloxacin accumulating in the cytoplasm, the 
disulfide was coupled at carboxylic group of ciprofloxacin, therefore cleaving the bond is 
essential for antimicrobial activity. 
              The inefficient release of ciprofloxacin could possibly be due to insufficient 
sulfhydryl concentration in the E. coli cytoplasm leading to slow kinetics of the reduction 
of the disulfide bond by sulfhydryl-containing species since the reduction rate is linearly 
dependent on the concentration of the reducing agent.68 
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Figure 48: Bacterial growth curve of E. coli BW25113 grown with 1.0 μM (A) and 10 μM 
(B) additives. Error bars are ± standard deviation of three biological replicates 
 
              The hypothesis of intracellular disulfide bond cleavage was proven to be 
successful but no evidence of active transport of the conjugates by peptide transporters 
was observed. However, the possibility of active transport by peptide transporters 
cannot be ruled out without trying other peptides with hydrophobic or polar side chains 
such as serine.41   
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Chapter 3: Conclusions and future work  
3.1. Conclusions 
              Trojan Horse conjugates were successfully prepared by connecting the 
fluoroquinolone ciprofloxacin to a single amino acid, Ala, and the dipeptide, Ala-Ala, 
through a non-biolabile amide bond and a biolabile disulfide linker. The conjugates were 
fully characterised and screened against the E. coli BW25113 bacterial strain.   
              Conjugate 38, with a non-biolabile amide bond, was prepared by coupling Ala-
Ala to the piperazinyl nitrogen of ciprofloxacin. Compound 38 was found to be 
significantly less active than the parent drug ciprofloxacin and also the single amino acid 
Ala conjugate 46. DNA gyrase assay of 38 showed that the lack of activity of the 
conjugate is due to ciprofloxacin losing its activity, this suggests that the nutrient Ala-Ala 
significantly interferes with the inhibition of DNA gyrase and this could be due to steric 
bulk or electronic properties of the dipeptide preventing the effective formation of the 
DNA-enzyme-drug complex which is critical for the antimicrobial activity of 
fluoroquinolones.  
               Conjugates 39 and 40 were prepared by coupling Ala and Ala-Ala respectively to 
the carboxylic group of ciprofloxacin through a biolabile disulfide linker. Both 
conjugates, 39 and 40, retained antimicrobial activity albeit lower than that of the 
parent drug, ciprofloxacin. This outcome supports the hypothesis of intracellular thiol-
induced disulfide bond cleavage since the carboxylic group of ciprofloxacin is required 
for activity. However no significant difference was observed between the antimicrobial 
activity of 39 and 40, with both conjugates found to be less active than ciprofloxacin, this 
suggests lack of active transport of the conjugates by peptide transporters as increased 
antimicrobial activity of 40 compared to 39 was expected since secondary peptide 
transporters have higher affinity for dipeptides than single amino acids. Therefore 39 
and 40 could possibly be entering the bacterial inner membrane by passive diffusion.  
              The reduced antimicrobial activity of 39 and 40 is thought to either be due to 
inefficient thiol-induced cleavage of the disulfide bond or slow ciprofloxacin release after 
disulfide cleavage, however, these hypotheses have not been investigated.  
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3.2. Future work  
              As no active transport of the synthesised conjugates by peptide transporters 
across the bacterial inner membrane was observed, it would be advantageous to 
investigate other peptides possessing hydrophobic or polar side chains before ruling out 
the hypothesis.  
              Although the hypothesis of intracellular disulfide bond cleavage was confirmed, 
the cleavage of the disulfide bond was not monitored. Monitoring the cleavage process 
will allow investigation of the kinetics of the reduction process as well as reveal the 
fragments produced. It would also be advantageous to investigate the effect of the 
disulfide bond coupled at the piperazinyl nitrogen of ciprofloxacin as this will allow 
direct comparison with conjugates 39 and 40 which have the disulfide bond coupled at 
the carboxylic group of ciprofloxacin.   
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Chapter 4: Experimental  
4.1. General  
           1H NMR (400 MHz) and 13C NMR (100 MHz) and 19F NMR (376 MHz) spectra were 
recorded on a Jeol ECX-400 (400 MHz) spectrometer with chemical shifts quoted in parts 
per million relative to the stated deuterated solvents; CHCl3 [δH 7.26 and δC 77.16], D2O 
[δH 4.79] and CD3OD [δH 3.31 and δC 49.00]. Coupling constant (J) are quoted in Hertz. 
Carbon NMR spectra were assigned using DEPT experiments. 1D spectra were processed 
using Bruker WinNMR software and 2D spectra using Jeol Delta software. Positive and 
negative electrospray (ESI) mass spectra were acquired on a Finnigan LCQ mass 
spectrometer or a Bruker MicroToF mass spectrometer. Infra-red spectra were recorded 
on an ATI Mattson Genesis FT-IR spectrometer. All samples were dried under vacuum 
before analysis. Melting points were recorded using a Bibby Stuart melting point 
apparatus and are uncorrected. 
 
              All solvents and chemical reagents were supplied by Aldrich or the Fischer 
Scientific. Solvents were used as received or dried over 4 Angstrom (Å) molecular sieves 
prior to use where necessary. Deionised water was used for all synthetic procedures. 
Analytical thin layer chromatography was performed using Merck F254 aluminium-backed 
plates using the specified solvent system and visualised through ultraviolet light (254 nm 
or 365 nm) with indicators such as iodine and potassium permanganate where 
necessary. Flash column chromatography was carried out using Davisil Flash Silica, 35-70 
micron and the specified eluent. Dry-freezing was carried out by freezing the reaction 
mixture using liquid nitrogen (N2). 
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4.2. Synthesis of Ala-Ala-ciprofloxacin conjugate 38 
Compound 41 
 
 
              Thionyl chloride (15.0 mL, 205.64 mmol) was added dropwise to a stirred 
solution of ciprofloxacin (3.36 g, 10.14 mmol) in dry methanol (100 mL) at 0-50C. The 
reaction mixture was heated under reflux for 17 hours. The reaction mixture was cooled 
to room temperature and concentrated in vacuo to yield a yellow oil. 
              The oil was taken up in aqueous potassium carbonate (25 mL) and extracted 
with DCM (4 x 40 mL). The organic layer was washed with deionised water (40 mL) and 
re-extracted with DCM (3 x 40 mL) then dried over MgSO4, filtered and concentrated in 
vacuo to yield a white powder 41.  
Yield: 
2.10 g, 60% 
m.p. (OC)  
223.5 – 243.4  
m/z (ESI): 
346 ([M+H]+, 100%)   
HRMS (ESI): 
Calc. for C18H21FN3O3 [M+H]
+ 346.1561, found 346.1547 (3.7 ppm mean error) 
89 
 
 
1H NMR: (400 MHz, CD3OD) δH (ppm): 
8.64 (s, 1H, H-8, CH), 7.84 (d, 3JH-F = 13.3 Hz, 1H, H-6, CH), 7.48 (d, 
4JH-F = 6.9 Hz, 1H, H-3, 
CH), 3.85 (s, 3H, H-22, CH3), 3.63-3.65 (m, 1H, cyclopropane, CH), 3.26-3.28 (m, 4H, 
piperazine, CH2), 3.03 (m, 4H, piperazine, CH2), 1.33-1.39 (m, 2H, cyclopropane, CH2), 
1.16-1.18 (m, 2H, cyclopropane, CH2)  
13C NMR: (100 MHz, CD3OD) δc (ppm): 
175.25 (d, 4JC-F = 3.0 Hz, C-10), 168.92 (C-18), 156.04 (d, 
1JC-F = 249.0 Hz, C-1), 149.97 (C-
8), 146.58 (d, 2JC-F = 10.7 Hz, C-2), 139.76 (C-9), 123.15 (d, 
3JC-F= 7.3 Hz, C-5), 113.01 (d, 
2JC-F = 23.0 Hz, C-6), 110.30 (C-4), 106.89 (d,
3JC-F= 2.3 Hz, C-3), 51.63 (C-22), 50.9 (C-
12/13/15/16), 49.58 (C-12/13/15/16), 46.34 (C-12/13/15/16), 36.19 (C-23), 8.44 (C-24, 
25) 
IR (KBr cm-1): 
1724 (C=O), 1617 (C=O), 1311 (C-O), 1068 (C-O) 
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Compound 43 
 
              To stirred suspension of compound 41 (0.41 g, 1.20 mmol), compound 42 (0.25 
g, 0.96 mmol) and HOBt.H2O (0.21 g, 1.55 mmol) in dry DMF (25 mL) was added EDC.HCl 
(0.3 g, 1.56 mmol) and DIPEA (0.30 mL, 1.70 mmol). The reaction mixture was stirred at 
room temperature for 17 hours.  
              The reaction mixture was concentrated in vacuo to yield a yellow viscous oil. The 
oil was taken up in deionised water (50 mL) and extracted with DCM (3x70 mL). The 
organic extracts were combined and washed with deionised water (50 mL), 0.1M HCl (40 
mL), aqueous NaHCO3 (40 mL), brine (40 mL) and deionised water (50 mL). The organic 
layer was dried over MgSO4 filtered then concentrated in vacuo to yield a viscous yellow 
oil. The crude product was purified by column chromatography on silica gel eluting with 
7% propan-2-ol in CHCl3 to obtain a yellowish solid 43.   
Rf:  0.40 
Yield: 
0.24 g, 43% 
m.p. (OC)  
112.3 – 117.3 
m/z (ESI): 
610 ([M+Na]+, 100%)   
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HRMS (ESI): 
Calc. for C29H38FN5NaO7 [M+Na]
+ 610.2647, found 610.2662 (-2.1 ppm mean error) 
1H NMR: (400 MHz, CDCl3) δH (ppm): 
8.42 (s, 1H, H-8, CH), 7.85 (d, 3JH-F = 13.3 Hz, 1H, H-6, CH), 7.29(d, 
4JH-F = 6.9 Hz, 1H, H-3, 
CH),7.21(m, 1H, H-29/33, NH), 5.31 (m,1H, H-29/33, NH), 4.90(m, 1H, H-27/32, CH), 4.18 
(m, 1H, H-27/32, CH), 3.83 (s, 3H, H-22, CH3), 3.64-3.77(m, 4H, piperazine, CH2), 3.40-
3.42(m, 1H, cyclopropane, CH), 3.13-3.24 (m, 4H, piperazine, CH2), 1.38 (s, 9H, H-
39,40,41, CH3), 1.31-1.34 (m, 6H, H-30,42, CH3), 1.26-1.29 (m, 2H, cyclopropane, CH2), 
1.08-1.12 (m, 2H, cyclopropane, CH2)  
13C NMR: (100 MHz, CDCl3) δc (ppm): 
172.25 (d, 4JC-F = 3.0 Hz, C-10), 170.46 (C-35), 165.77 (C-18), 162.41 (C-26,31), 154.60 (d, 
1JC-F = 249.0 Hz, C-1), 148.27 (C-8), 143.50 (d, 
2JC-F = 10.7 Hz, C-2), 137.70 (C-9), 123.17 (d, 
3JC-F= 7.3 Hz, C-5), 113.07 (d, 
2JC-F = 23.0 Hz, C-6), 109.63 (C-4), 105.25 (d,
3JC-F= 2.3 Hz, C-
3), 79.75 (C-38), 51.81 (C-22), 45.12 (C-12/13/15/16), 44.83 (C-12/13/15/16), 41.76 (C-
12/13/15/16), 34.47 (C-23), 28.13 (C-39, 40, 41), 25.15 (C-27, 32), 18.52 (C-30, 42),7.97 
(C-24, 25) 
IR (KBr cm-1): 
3300 (N-H), 1620 (C=O), 1162 (C-O), 1021 (C-O) 
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Compound 44 
 
              Compound 43 (0.10 g, 0.20 mmol) was taken up in 20% TFA in dry CHCl3 (10 mL) 
and left stirring at room temperature for 24 hours. The reaction mixture was 
concentrated under vacuum to yield an orange residue. The residue as taken up in 
ethanol (5 x 10mL) and concentrated in vacuo to give a yellow oil 44.  
Yield: 
0.10 g, 84% 
m/z (ESI): 
488 ([M+H]+, 100%) 
HRMS (ESI): 
Calc. for C24H31FN5O5 [M+H]
+488.2304, found 488.2305 (-0.3 ppm mean error) 
1H NMR: (400 MHz, D2O) δH (ppm): 
8.39 (s, 1H, H-8, CH), 7.73 (d, 3JH-F = 13.3 Hz, 1H, H-6, CH), 7.23(d, 
4JH-F = 6.9 Hz, 1H, H-3, 
CH), 4.65 (m, 1H, H-27/32, CH), 4.18 (m, 1H, H-27/32, CH), 3.65 (s, 3H, H-22, CH3), 3.54-
3.66(m, 4H, piperazine, CH2), 3.40-3.42(m, 1H, cyclopropane, CH), 3.13-3.24 (m, 4H, 
piperazine, CH2), 1.45-1.51 (m, 3H, H-30/35, CH3), 1.28-1.30 (m, 3H, H-30/35, CH3), 1.17 
(m, 2H, cyclopropane, CH2), 1.08 (m, 2H, cyclopropane, CH2)  
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13C NMR: (100 MHz, D2O) δc (ppm): 
171.99 (d, 4JC-F = 3.0 Hz, C-10), 168.34 (C-18), 162.58 (C-26,31), 157.99 (d, 
1JC-F = 249.0 Hz, 
C-1), 149.60 (C-8), 142.40 (d, 2JC-F = 10.7 Hz, C-2), 136.24 (C-9), 122.36 (d, 
3JC-F= 7.3 Hz, C-
5), 113.32 (d, 2JC-F = 23.0 Hz, C-6), 109.20 (C-4), 104.89 (d,
3JC-F= 2.3 Hz, C-3), 55.75 (C-22), 
47.46 (C-12/13/15/16), 47.17 (C-12/13/15/16), 44.55 (C-12/13/15/16), 40.39 (C-23), 
33.86 (C-27, 32), 15.13 (C-30, 35), 5.60 (C-24, 25) 
19F NMR: (376 MHz, D2O) δF (ppm): 
-126.76 (dd, JH-F = 13.0, 8.0 Hz, F-17), -76.76 (F-1) 
IR (KBr cm-1): 
3300 (N-H), 1620 (C=O), 1162 (C-O), 1021 (C-O) 
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Compound 45 
 
              To a solution of compound 44 (0.08 g, 0.17 mmol) in 5:1 methanol: water (10 
mL) was added 1M NaOH in methanol (1.3 mL) and the reaction mixture was left stirring 
for 26 hours. The reaction mixture was neutralised with 1M HCl to pH ~ 8 then 
concentrated under vacuum to give a yellow solid 45. 
Yield: 
0.09 g, 93%  
m.p. (OC)  
232 – 235.1  
m/z (ESI): 
474 ([M+H]+, 100%) 
HRMS (ESI): 
Calc. for C23H29FN5O5 [M+H]
+ 474.2147, found 474.2134 (2.6 ppm mean error) 
1H NMR: (400 MHz, CD3OD) δH (ppm): 
8.37 (s, 1H, H-8, CH), 7.75 (d, 3JH-F = 13.3 Hz, 1H, H-6, CH), 7.23(d, 
4JH-F = 6.9 Hz, 1H, H-3, 
CH), 4.60 (m, 1H, H-27/32, CH), 4.15 (m, 1H, H-27/32, CH), 3.45-3.53(m, 4H, piperazine, 
CH2), 3.39-3.42(m, 1H, cyclopropane, CH), 3.13-3.24 (m, 4H, piperazine, CH2), 1.45-1.51 
(m, 3H, H-30/35, CH3), 1.29 (m, 3H, H-30/35, CH3), 1.17 (m, 2H, cyclopropane, CH2), 1.05 
(m, 2H, cyclopropane, CH2)  
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13C NMR: (100 MHz, CD3OD) δc (ppm): 
175.62 (d, 4JC-F = 3.0 Hz, C-10), 172.65 (C-26, 31), 163.21 (C-18),  154.0 (d, 
1JC-F = 249.0 Hz, 
C-1), 146.97 (C-8), 143.64 (d, 2JC-F = 10.7 Hz, C-2), 138.54 (C-9), 122.06 (d, 
3JC-F= 7.3 Hz, C-
5), 115.24 (d, 2JC-F = 23.0 Hz, C-6), 111.35 (C-4), 106.69 (d,
3JC-F= 2.3 Hz, C-3), 49.45 (C-
12/13/15/16), 46.04 (C-12/13/15/16), 45.30 (C-12/13/15/16), 34.93 (C-23), 18.95 (C-27, 
32), 16.19 (C-30, 35), 7.49 (C-24, 25) 
19F NMR: (376 MHz, D2O) δF (ppm): 
-126.78 (dd, JH-F = 13.0, 8.0 Hz, F-17), -76.76 (F-1) 
IR (KBr cm-1): 
3374 (N-H), 1621 (C=O), 1238 (C-O), 1020 (C-O) 
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4.3. Synthesis of cip-link-Ala conjugate 39 
Compound 50 
 
              Ciprofloxacin (2.01 g, 6.07 mmol) was dissolved in water : dioxane (1:1, 20 mL) 
containing 1M NaOH (10 mL) and was left stirring for an hour. Di-tert-butylcarbonate 
(2.53 g, 11.59 mmol)   was taken up in dioxane (2 mL) before adding it to the reaction 
mixture. The reaction was continued for 24 hours. Approximately three quarters of the 
solvent (15 mL) was removed in vacuo, and acetone (40 mL) was added to the residue. 
The solid white product was filtered, thoroughly washed with acetone and dried under 
vacuum to yield a white powder 50. 
Yield: 
2.46g, 94% 
Mp: 
247.0 – 250.9oC 
m/z (ESI): 
454.18 ([M+Na]+, 100%) 
HRMS (ESI): 
Calc. for C22H26FN3NaO5 [M+Na]
+ 454.1749, found 454.1748 (-0.0 ppm mean error) 
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1H NMR: (400 MHz, CDCl3) δH (ppm):  
8.74 (s, 1H, H-8, CH), 7.98 (d, 3JH-F = 13.3 Hz, 1H, H-6, CH), 7.36 (d, 
4JH-F = 6.9 Hz, 1H, H-3, 
CH), 3.68-3.64 (m, 4H, piperazine, CH2 ), 3.53 (m, 1H, cyclopropane, CH), 3.29-3.27 (m, 
4H, piperazine, CH2), 1.48 (s, 9H, tert-butyl, CH3), 1.41-1.36 (m, 2H, cyclopropane, CH2), 
1.23-1.17 (m, 2H, cyclopropane, CH2) 
13C NMR: (100 MHz, CDCl3) δc (ppm): 
177.03 (d, 4JC-F = 3.0 Hz, C-10), 169.98 (C-22), 166.89 (C-29), 154.54 (d, 
1JC-F = 249.0 Hz, C-
1), 147.47 (C-8), 145.77 (d, 2JC-F = 10.7 Hz, C-2), 139.01 (C-9), 123.48 (d, 
3JC-F= 7.3 Hz, C-5), 
112.48 (d, 2JC-F = 23.0 Hz, C-6), 108.13 (C-4), 104.99 (d,
3JC-F= 2.3 Hz, C-3), 80.34 (C-25), 
70.01 (C-14/15/17/18), 69.66 (C-14/15/17/18), 49.77 (C-14/15/17/18), 49.81 (C-
14/15/17/18) 35.28 (C-19), 28.37 (C-26, 27, 28), 8.22 (C-20, 21) 
IR (KBr cm-1): 
1731.7 (C=O), 1688.3 (C=O), 1628.0 (C=O), 1247.9 (C-O)   
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Compound 54 
 
              To a solution of 2,2’-dithiodiethanol 48 (4.12 g, 26.71 mmol) dissolved in DCM 
(50 mL) was added acetic anhydride (1.40 mL, 14.81 mmol) and pyridine (10.50 mL, 
129.82 mmol) and the mixture was stirred for 23 hours at room temperature. The 
reaction mixture was concentrated in vacuo yielding a yellow oil which was then 
partioned between ethyl acetate (30 mL) and 1M HCl (35 mL). The organic layer was 
washed with water (25 mL) and brine (25 mL), dried over anhydrous sodium sulphate 
(Na2SO4) filtered and concentrated in vacuo to yield a yellow viscous oil. The crude 
product was then purified by silica gel column chromatography using 40% EtOAc in 
petroleum ether to yield a pale yellow viscous oil 54. 
Yield:  
0.76g , 26% 
m/z (ESI): 
219.01 ([M+Na]+, 100%)   
HRMS (ESI): 
Calc. for C6H12NaO3S2 [M+Na]
+ 219.0120, found 219.0117 (1.6 ppm mean error) 
1H NMR: (400 MHz, CDCl3) δH (ppm):   
4.35 (t, J = 6.0 Hz, 2H, H-2/7, CH2), 3.90 (t, J = 6.0 Hz, 2H, H-2/7, CH2), 2.95-2.87 (m, 4H, 
H-3, 6), 2.09 (s, 3H, H-10),  
13C NMR: (100 MHz, CDCl3) δc (ppm): 
170.93 (C-9), 62.35 (C-2/7), 60.18 (C-2/7), 41.58 (C-3/6), 36.92 (C-3/6), 20.87 (C-10) 
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Compound 55 
                 Compound 50 (0.5 g, 1.16 mmol) was dissolved in dry DCM (50 mL) then DMAP 
(0.21 g, 1.73 mmol), HATU (0.66 g, 1.74 mmol) was added with continuous stirring at 
room temperature forming a yellow suspension.  Shortly after DIPEA (0.45 mL, 2.60 
mmol) was added to the mixture followed by compound 54 (0.26 g, 1.33 mmol) taken up 
in approx. 2 mL dry DCM. The reaction mixture was left stirring at room temperature for 
72 hours and a clear yellow solution was observed. DCM (30 mL) was added to the 
reaction mixture and extracted with water (30 mL). The organic layer was washed with 
saturated Na2CO3 and water (30 mL each) then dried over MgSO4 filtered and 
concentrated in vacuo yielding the crude product. The crude product was purified by 
column chromatography on silica gel eluting with 5% MeOH in CHCl3 to obtain a pale 
yellow oil 55.  
Rf: 
0.30 
Yield: 
0.24g, 34% 
m/z (ESI): 
632.19 ([M+Na]+, 100%) 
HRMS (ESI): 
Calc. for C28H36FN3NaO7S2 [M+Na]
+ 632.1871, found 632.1859 (1.9 ppm mean error) 
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1H NMR: (400 MHz, CDCl3) δH (ppm):   
8.34 (s, 1H, H-8, CH), 7.74 (d, 3JH-F = 13.3 Hz, 1H, H-6, CH), 7.15 (d, 
4JH-F = 6.9 Hz, 1H, H-3, 
CH), 4.45-4.42 (m, 2H, H-25/33, CH2), 4.25-4.23 (m, 2H, H-25/33, CH2), 3.56 (m, 4H, 
piperazine, CH2), 3.41-3.38 (m, 1H, cyclopropane, CH), 3.12 (m, 4H, piperazine, CH2), 
2.99-2.96 (m, 2H, H-26/29, CH2), 2.89-2.85 (m, 2H, H-26/29, CH2), 1.98 (s, 3H, H-34, CH3), 
1.41 (s, 9H, tert-butyl, CH3), 1.25 (m, 2H, cyclopropane, CH2), 1.08 (m, 2H, cyclopropane, 
CH2) 
13C NMR: (100 MHz, CDCl3) δc (ppm): 
172.25 (d, 4JC-F = 3.0 Hz, C-10), 170.28 (C-35), 165.21 (C-22), 164.17 (C-31), 154.04 (d, 
1JC-F 
= 249 Hz, C-1), 147.83 (C-8), 143.84 (d, 2JC-F = 10.7 Hz, C-2), 137.36 (C-9), 122.35 (d, 
3JC-F = 
7.3 Hz, C-5), 112.35 (d, 2JC,F = 23.0 Hz, C-6), 108.80 (C-4), 104.80 (d, 
3JC-F = 2.3Hz, C-3), 
79.65 (C-38), 61.91(C-17/18/20/21) 61.80 (C-17/18/20/21), 49.37 (C-17/18/20/21), 
49.30 (C-17/18/20/21), 38.11 (C-25, 33),  36.65 (C-26, 29), 34.22 (C-13), 27.93 (C-39, 40, 
41), 20.39 (C-34) 7.64 (C-14, 15) 
IR (KBr cm-1): 
 1735.03 (C=O), 1720.18 (C=O), 1689.05 (C=O), 1242.74 (C-O), 1159.96 (C-O) 
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Compound 57 
 
              Compound 50 (0.49 g, 1.15 mmol) was dissolved in dry DCM (50 mL) then DMAP 
(0.22 g, 1.76 mmol), HATU (0.66 g, 1.75 mmol) was added with continuous stirring at 
room temperature forming a yellow suspension.  Shortly after DIPEA (0.45 mL, 2.60 
mmol) was added to the mixture followed by 2,2’-dithiodiethanol 48 (0.26 g, 1.33 mmol) 
taken up in approx. 2 mL dry DCM. The reaction mixture was left stirring at room 
temperature for 23 hours and a clear yellow solution was observed. DCM (30 mL) was 
added to the reaction mixture and extracted with water (30 mL). The organic layer was 
washed with saturated Na2CO3 and water (30 mL each) then dried over MgSO4 filtered 
and concentrated in vacuo yielding an off white paste-like crude product compound 51 
which was used without further purification.  
              Approx. 0.40mmol of the crude product 51 was dissolved in dry DCM (30 mL) 
with stirring and compound 56 (0.08 g, 0.45 mmol) was added to the solution. DMAP 
(0.08 g, 0.65 mmol), DIPEA (0.14 mL, 0.80 mmol) and EDC (0.13 g, 0.66 mmol) were 
added to the reaction mixture and this was allowed to stir at room temperature for 19 
hours. The reaction mixture was concentrated under vacuum and a yellow oil was 
obtained. The oil was then taken up in DCM (15 mL) and extracted with water (10 mL). 
The organic layer was separated, washed with Na2CO3 (2 x 10 mL) and water (2 x 10 mL) 
then dried over Na2SO4 filtered and concentrated in vacuo yielding a yellowish oil. The 
crude product was purified by silica gel column chromatography using 25% acetone in 
DCM to yield a pale yellow oil 57.  
Rf: 
0.37 
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Yield: 
0.10g, 35% 
m/z (ESI): 
761.27 ([M+Na]+, 100%) 
HRMS (ESI): 
Calc. for C34H47FN4NaO9S2 [M+Na]
+ 761.2661, found 761.2651 (1.0ppm mean error) 
1H NMR: (400 MHz, CDCl3) δH (ppm):   
8.23 (s, 1H, H-8, CH), 7.58 (d, 3JH-F = 13Hz, 1H, H-6, CH), 7.07 (d, 
3JH-F = 6.9Hz, 1H, H-3, 
CH), 4.12-4.36 (m, 5H, H-25, 30, 41, CH2, CH), 3.49 (m, 4H, piperazine, CH2), 3.33 (m, 1H, 
cyclopropane, CH), 3.05 (m, 4H, piperazine, CH2), 2,90 (m, 2H, H-26/29, CH2), 2.82 (m, 
2H, H-26/29, CH2), 1.34 (s, 9H, tert-butyl, CH3), 1.27 (m, 12H, tert-butyl, H-43, CH3), 1.16 
(m, 2H, cyclopropane, CH2), 1.02 (m, 2H, cyclopropane, CH2) 
13C NMR: (100 MHz, CDCl3) δc (ppm): 
172.80 (C-10), 172.57 (C-31, 44), 164.81 (C-22, 39), 154.21 (d, 1JC-F = 249 Hz, C-1), 148.04 
(C-8), 144.10 (d, 2JC-F = 10 Hz, C-2), 137.57(C-9), 122.85 (d, 
3Jc-F = 6 Hz,  C-5), 113.12 (d, 
2JC-F = 23 Hz, C-6), 109.37 (C-4), 104.70 (d, 
3JC-F = 3.0 Hz, C-3), 79.82 (C-34, 46), 62.53 ( C-
17/18/20/21), 62.41(C-17/18/20/21) 62.16 (C-17/18/20/ 21), 60.50 ( C-17/18/20/21),  
36.68 (C-25, 30),  36.58 (C-26, 29), 34.23 (C-13/41), 30.55 (C-13/41), 28.02 (C-35, 
36,37/48, 49, 50), 27.94 (C-35, 36, 37/ 48, 49,50 ), 18.14 (C-43), 7.80 (C-14, 15) 
IR (KBr cm-1): 
3300.81 (N-H), 1694.04 (C=O), 1621.02 (C=O), 1245.13 (C-O), 1160.16 (C-O) 
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Compound 58 
 
              Compound 57 (0.17 g, 0.23 mmol) was taken up in 20% TFA in dry DCM (10 mL) 
to give a yellow solution which was left stirring at room temperature for 23 hours. The 
reaction mixture was concentrated under vacuum yielding a dark orange residue. The 
residue was taken up in ethanol (5 x 10 mL) and concentrated under vacuum, yielding a 
yellowish oil 58.    
Yield: 
0.16g, 91% 
m/z (ESI): 
270.09 ([M]2+,100%) 
HRMS (ESI): 
Calc. for C24H33FN4O5S2 [M]
2+ 270.0933, found 270.0920 (4.4ppm mean error) 
1H NMR: (400 MHz, CD3OD) δH (ppm): 
8.65 (s, 1H, H-8, CH), 7.77 (d, 3JH-F = 13Hz, 1H, H-6, CH), 7.52 (d, 
3JH-F = 6.9Hz, 1H, H-3, 
CH), 4.45-4.56 (m, 4H, H-25,30, CH2), 4.14-4.20 (m, 1H, H-34, CH), 3.68 (m, 1H, 
cyclopropane, CH), 3.59(m, 4H, piperazine, CH2 ), 3.50 (m, 4H, piperazine, CH2), 3.10-
3.03 (m, 4H, H-26,29, CH2), 1.59 (m, 3H, H-33, CH3), 1.39 (m, 2H, cyclopropane, CH2), 
1.20 (m, 2H, cyclopropane, CH2) 
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13C NMR: (100 MHz, CD3OD) δc (ppm): 
171.10 (C-10), 167.35 (C-22, 32), 155.81 (1JC,F = 249 Hz, C-1), 150.34 (C-8), 145.01 (
2JC,F = 
10 Hz, C-2), 139.64 (C-9), 128.86 (C-5), 113.24 (2JC,F = 23 Hz, C-6), 109.32 (C-4), 107.89 (C-
3), 64.52(C-17/18/20/21) 63.71 (C-17/18/20/21), 44.58 (C-13/34), 37.99 (C-25, 30), 
37.53 (C-26, 29), 36.43 (C-13/34), 16.19 (C-33), 8.59 (C-14, 15) 
19F NMR: (376 MHz, D2O) δF (ppm): 
-124.56 (dd, JH-F = 13.0, 8.0 Hz, F-17), -76.94 (F-1) 
IR (KBr cm-1): 
3375.00 (N-H), 1750.48 (C=O), 1673.57 (C=O), 1621.44 (C=O), 1171.06 (C-O) 
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4.4. Synthesis of cip-link-Ala-Ala conjugate 40 
Compound 60 
 
 
              Approx. 0.70 mmol of compound 51 was dissolved in dry DCM (30 mL) with 
stirring and compound 59 (0.16 g, 0.61 mmol) was added to the solution. DMAP (0.10 g, 
0.86 mmol), DIPEA (0.17 mL, 1.00 mmol) and EDC (0.17 g, 0.89 mmol) were added to the 
reaction mixture and this was allowed to stir at room temperature for 19 hours. The pale 
yellow reaction mixture was then taken up in water (25 mL) and extracted with DCM (2 x 
25 mL). The organic layers were combined and washed with NaHCO3 (2 x 25 mL), Brine 
(2 x 25 mL) and water (2 x 25 mL) then dried over Na2SO4 filtered and concentrated in 
vacuo yielding a yellow oil. The crude product was purified by silica gel column 
chromatography using 25% acetone in DCM to yield a pale yellow oil 60.  
Rf: 
0.57 
Yield: 
0.15g, 30% 
m/z (ESI): 
832.30 ([M+Na]+, 100%)  
HRMS (ESI): 
Calc. for C37H52FN5NaO10S2 [M+Na]
+ 832.3032, found 832.3050 (-2.6ppm mean error) 
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1H NMR: (400 MHz, CDCl3) δH (ppm): 
8.50 (s, 1H, H-8, CH), 7.96 (d, 3JH-F = 13Hz, 1H, H-6, CH), 7.25 (d, 
3JH-F = 6.9Hz, 1H, H-3, 
CH), 4.35-4.54 (m, 5H, H-25, 30, CH2, 41/46, CH), 4.21 (m, 1H, H-41/46, CH), 3.63 (m, 4H, 
piperazine, CH2), 3.44 (m, 1H, cyclopropane, CH), 3.20 (m, 4H, piperazine, CH2), 3.04-
3.02 (m, 2H, H-26/29, CH2), 2.95-2.93 (m, 2H, H-26/29, CH2), 1.47 (s, 9H, tert-butyl, CH3 
), 1.41 (s, 10H, tert-butyl, H-43/48, CH3), 1.33 (m, 5H, H-43, 48), 1.23 (m, 2H, 
cyclopropane, CH2), 1.13 (m, 2H, cyclopropane, CH2) 
13C NMR: (100 MHz, CDCl3) δc (ppm): 
172.63 (C-10), 170.15 (C-31, 49), 172.09 (C-44), 164.60 (C-22, 39), 154.22 (d, 1JC,F = 249 
Hz, C-1), 148.03 (C-8), 144.13 (d, 2JC,F = 10 Hz, C-2), 137.58(C-9), 122.72 (d, 
3Jc-F = 6 Hz, C-
5), 112.94 (d, 2JC,F = 23 Hz, C-6), 109.21 (C-4), 104.70 (d, 
3JC-F = 3.0 Hz, C-3), 79.81 (C-34, 
52), 62.27(C-17/18/20/21) 62.18 (C-17/18/20/21), 36.70 (C-25, 30),  36.58 (C-26, 29), 
34.27 (C-13/41/46), 29.28 (C-13/41/46), 28.01 (C-35, 36, 37/53, 54, 55), 27.91 (C-35, 36, 
37/53, 54, 55), 17.63 (C-43, 48), 7.79 (C-14, 15) 
IR (KBr cm-1): 
3314.16 (N-H), 1689.41 (C=O), 1620.33(C=O), 1245.41 (C-O), 1161.30 (C-O) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
 
Compound 61 
 
              Compound 60 (0.11 g, 0.14 mmol) was taken up in 20% TFA in dry DCM (10 mL) 
to give a yellow solution which was left stirring at room temperature for 23 hours. An 
orange solution was observed and this was concentrated under vacuum yielding a dark 
orange residue. The residue was taken up in ethanol (5 x 10 mL) and concentrated in 
vacuo, yielding a yellowish oil 61. 
Yield: 
0.10 g, 87% 
m/z (ESI): 
305.61 ([M]2+,100%) 
HRMS (ESI): 
Calc. for C27H38FN5O6S2 [M]
2+ 305.6118, found 305.6110 (1.6 ppm mean error) 
1H NMR: (400 MHz, CD3OD) δH (ppm): 
8.70 (s, 1H, H-8, CH), 7.83 (d, 3JH-F = 13Hz, 1H, H-6, CH), 7.55 (d, 
3JH-F = 6.9Hz, 1H, H-3, 
CH), 4.38-4.46 (m, 4H, H-25, 30), 3.98-4.02 (m, 1H, H-41/46, CH), 3.79 (m, 1H, H-41/46, 
CH), 3.69 (m, 1H, cyclopropane, CH), 3.60 (m, 4H, piperazine, CH2), 3.51 (m, 4H, 
piperazine, CH2), 2.82-3.02 (m, 4H, H-26, 29, CH2), 1.54 (m, 3H, H-43/48, CH3), 1.39-1.41 
(m, 5H, H-43/48, CH3, cyclopropane, CH2 ), 1.18 (m, 2H, cyclopropane, CH2) 
 
13C NMR: (100 MHz, CD3OD) δc (ppm): 
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174.00 (C-10), 170.60 (C-44), 163.23 (C-22, 39), 154.22 (d, 1JC,F = 249 Hz, C-1), 148.03 (C-
8), 144.13 (d, 2JC,F = 10 Hz, C-2), 137.58(C-9), 122.72 (d, 
3Jc-F = 6 Hz, C-5), 117.87 (d, 
2JC,F = 
23 Hz, C-6), 109.21 (C-4), 105.51 (d, 3JC-F = 3.0 Hz, C-3), 63.49(C-17/18/20/21) 59.21 (C-
17/18/20/21), 49.02 (C-25, 30),  40.01 (C-26, 29), 38.04 (C-13/41/46), 36.20 (C-
13/41/46), 16.50 (C-43/48), 15.88 (C-43/48), 7.43 (C-14, 15) 
19F NMR: (376 MHz, D2O) δF (ppm): 
-124.50 (dd, JH-F = 13.0, 8.0 Hz, F-17), -76.87 (F-1) 
IR (KBr cm-1): 
3385.87 (N-H), 1667.57 (C=O), 1628.93(C=O), 1269.14 (C-O), 1198.95 (C-O), 1180.19 
 (C-O) 
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4.5. Biological procedures 
 
4.5.1. Plate reader assay 
 
              In vivo assay of BW25113 strain of wild type (WT) E. coli was carried out using 
sterile techniques, three liquid cultures of BW25113 were inoculated in 5ml of lysogenic 
broth (LB) each at 37oC overnight. 1 in 10 dilution of each culture was prepared in LB and 
normalised to OD650 = 2 with LB used as a blank.  
             A 96 well plate was prepared by adding sterile water (200 μl) into all perimeter 
wells to prevent evaporation, LB (198 μl) into blank wells (column 11), LB (193 μl) into all 
other wells except blank wells, antibiotic of specific concentrations (2 μl) into all wells 
(columns 2-10), specific normalised bacterial strain (5 μl) into all wells apart from water 
wells and blank columns, 0.1M acetic acid (2 μl) into blank wells and row B with 0 μM 
drug concentration. Row B was used as a control for all experiments with no conjugate 
or ciprofloxacin present, only normalised LB (a nutritionally rich medium) and 0.1M 
acetic acid, therefore measuring the OD650 of wild type E. coli BW25113. 
            The 96 well plate was placed into a BMG LabTech FLUOstar Omega plate reader 
and OD650 was measured every 30 minutes for 16 hours. The plate was shaken at 
200RPm in between measurements to keep aerobic bacterial growth. Optical densities 
from blank wells was subtracted from sample wells to obtain normalised OD 
measurements which was used for data analysis. Growth curves were plotted with error 
bars calculated as ± standard deviation of the three biological replicates for each 
experiment.   
 
4.5.2. Gyrase assay   
              In vitro assay of cip-diAla conjugate 38 was carried to test if the antibiotic was 
still active against DNA gyrase, a control experiment was performed using ciprofloxacin. 
E. coli gyrase supercoiling assay kit from Inspiralis was used to carry out the 
experiments.   
1 U of DNA gyrase was prepared by diluting the stock of 5 U/μl DNA gyrase solution with 
the provided dilution buffer. Samples of diluted DNA gyrase (2 μl) with relaxed pBR322 
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open complex bacterial plasmid (0.5 μl), assay buffer (6 μl), desired antibiotic 
concentration (1 μl) and sterile water to make up the reaction volume of 30μl were 
incubated at 37oC for 30 minutes. The conditions for each reaction are shown in Table 5 
below.  
Sample Antibiotic/ 
μl 
Dulited  
gyrase/μl 
Assay 
buffer/μl 
pBR322/μl Water/μl 
Positive control 0 2 6 0.5 21.5 
Negative control 0 0 6 0.5 23.5 
Antibiotic assay 1 2 6 0.5 20.5 
Table 5. Table showing the reaction conditions for each sample.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
 
Chapter 5: Appendices 
Appendix 1. 1H NMR of protected Ala-Ala-ciprofloxacin 43 
bs-013.2_Proton-1-1.esp
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Appendix 2. 13C NMR of protected Ala-Ala-ciprofloxacin 43 
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Appendix 3. 1H NMR of protected ciprofloxacin-disulfide-Ala 57  
bs-008.2d(v)_Proton-1-1.esp
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Appendix 4. 13C NMR of protected ciprofloxacin-disulfide-Ala 57  
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Appendix 5. 1H NMR of ciprofloxacin-disulfide-Ala 39  
bs-009.4_Proton-1-1.esp
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Appendix 6. 13C NMR of ciprofloxacin-disulfide-Ala 39  
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Appendix 7. 1H NMR of protected ciprofloxacin-disulfide-Ala-Ala 60  
bs-010.1a_Proton-1-1.esp
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Appendix 8. 13C NMR of protected ciprofloxacin-disulfide-Ala-Ala 60  
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Appendix 9. 1H NMR of ciprofloxacin-disulfide-Ala-Ala 40  
bs-011.1_Proton-1-1.esp
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Appendix 10. 13C NMR of ciprofloxacin-disulfide-Ala-Ala 40  
bs-011.1_Carbon-1-1.esp
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6. Glossary  
Biological  
ABC ATP Binding Cassette 
ADP Adenosine Diphosphate  
Ala Alanine 
Arg Arginine  
ATP Adenosine Triphosphate  
DNA Deoxyribosenucleic acid 
Glu Glutamic acid  
GSH Glutathione  
GSSG Glutathione disulfide 
LB Lysogenic Broth 
LPS Lipopolysaccharide 
Lys Lysine 
MDR Multi-drug resistance 
MFS Major Facilitator Superfamily 
MIC Minimal Inhibitory Concentration 
NADPH Nicotinamide adenine dinucleotide phosphate 
PBP Penicillin Binding Protein 
PepT Peptide Transporter 
PepTst Peptide Transporter from Shewanella aneidensis 
PepTso Peptide Transporter from Streptococcus 
thermophiles 
PEP-PTS Phosphoenolpyruvate-dependent sugar 
phosphotransferase system 
Pi Inorganic phosphate  
PTR / POT Proton-dependent Oligopeptide Transporter 
RNA Ribonucleic acid  
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Chemistry 
α Alpha 
β Beta 
Boc tert-Butyloxycarbonyl 
CD3OD Deuterated methanol 
CDCl3 Deuterated chloroform 
CHCl3 Chloroform 
Cip Ciprofloxacin 
Conc Concentration 
Dan Desferridanoxamine 
D2O Deuterated water 
DCC N,N’-Dicyclohexylcarbodiimide 
DCM Dichloromethane 
DIPEA N,N’-Diisopropylethylamine 
DMAP 4-Dimethylaminopyridine 
DMF Dimethylformamide 
EDC.HCl 1-Ethyl-3-(3’-dimethylaminopropyl)carbodiimide 
hydrochloride 
EtOAc Ethyl acetate 
H2SO4 Sulfuric acid 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate 
HBTU N,N,N’,N’-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate 
HCl Hydrochloric acid  
HOBt.H2O N-Hydroxybenzotriazolee hydrate  
Lor Lorabid® 
m.p. Melting point 
MeOH Methanol 
MgSO4 Magnesium Sulphate 
Na2CO3 Sodium Carbonate 
NaHCO3 Sodium Hydrogen Carbonate 
NaOH Sodium Hydroxide 
NHS N-Hydroxy Succinimide 
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NMR Nuclear Magnetic Resonance  
NO Nitric Oxide 
rt Room Temperature 
SOCl2 Thionyl Chloride 
TFA Trifuoroacetic acid  
Tri Trisclosan 
TLC Thin Layer Chromatography 
oC Degrees Centigrade 
μM Micromolar 
cm-1 Wavenumber 
g Grams 
g mol-1 Grams per mole 
hrs Hours 
Hz Hertz 
mM millimolar 
M Molar 
mol Moles 
Spectroscopy  
1H Proton 
13C Carbon 
19F Fluorine 
Calc Calculated 
COSY Correlation Spectroscopy 
δ Chemical Shift 
d doublet 
DEPT Distortionless Enhancement of Polarisation Transfer 
ESI Electronspray Ionisation 
m Multiplet 
m/z Mass to charge ratio 
ppm Parts per million 
Rf Retention factor 
s Singlet 
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